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ABSTRACT 
Stress was defined as “a specific response of the body to any non-specific demand 
(stressor) made on it”. When the real or perceived stressor is lasting or the response is 
inappropriate (distress), the physiological short-term changes switch to long-term 
alterations driving to pathological conditions, including mental illness. According to this 
“allostatic load” model, primary mediators such as catecholamines and steroid hormones 
trigger multi-systemic alterations of secondary signaling mediators possibly causing 
adverse manifestation in different body systems, including nervous and immune ones. 
Neurotrophins, in particular the Brain-Derived Neurotrophic Factor (BDNF), and immune 
mediators, like cytokines and chemokines, are possible modulators of the chronic stress 
response. Therefore, we aimed to assess their circulating levels in healthy persons in 
conditions of work-related stress. Before that, since measurement of peripheral BDNF is of 
great interest for psychiatrists but suffers for inconsistencies, possibly due to the lack of 
consistent procedures for BDNF samples collection and assessment, we aimed to 
overcome these limitations and defined a standardized methodology for both sample 
collection and BDNF measurement. Hence, we have selected the serum as the elective 
body fluid for BDNF quantification and, using sera from 40 healthy adult subjects, we 
compared the performance of six commercial BDNF ELISA kits. All kits showed 100% of 
sample recovery and, with one exception, comparable range. However, they exhibited very 
different inter-assay variations from 5% to 38%. Inter-assay variations, were higher than 
those declared by the manufacturers with only one exception which also had the best 
overall performance. Dot-blot analysis revealed that two kits selectively recognize mature 
BDNF, while the others reacted with both pro-BDNF and mature BDNF. Of note, having 
defined a standardized procedure which reduces the high variability due to technical, pre-
analytical and analytical steps, this study provides the basis to obtain an accurate measure 
BDNF in human serum, suitable for future clinical applications. 
As mentioned, the next step was to assess circulating BDNF and immune mediators in 
subjects with job-related stress. We therefore measured BDNF and, using the multiplex 
ELISA technology, other 48 analytes among cytokines, chemokines and growth factors in 
the sera of 122 healthy subjects (87 female and 35 male). The participants were enrolled 
among healthcare assistants and evaluated for work-related stress using psychophysical 
stress and burnout scales extracted from a self-assessed questionnaire standardized for 
the Italian context (Qu-BO test). Psychophysical stress addressed five items, namely 
anxiety, emotion (depression-like), gastrointestinal disturbances, cardiac disturbances, 
ergonomic dysfunction at the workplace and an overall stress state as the average of the 
five items; burnout state has been measured using three cores adapted from the Maslach 
Burnout Inventory, specifically emotional exhaustion, depersonalization and personal 
accomplishment. Higher scores mean higher stress status, except for personal 
accomplishment. We found that female had higher scores than male for all psychophysical 
stress items and for the emotional exhaustion core. Then, after correcting for gender and 
body-mass index (BMI), we attempted to correlate the biological variables with the score 
scales, using a combination of univariate (partial correlations) and multivariate analysis 
(partial least square and factor analysis) which took in account correlations among 
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analytes. As a result, we found no associations between burnout state and biological 
variables while, on the other hand, we detected negative associations between 
psychophysical stress items and some markers of the chemokine profile. In particular, we 
observed that levels of MCP-1/CCL2, CTACK/CCL27, RANTES/CCL5 and Eotaxin/CCL11 
negatively correlate, with different grade, with the scores of anxiety, gastric and cardiac 
problems and ergonomic dysfunction at the workplace. In addition, we observed IL-17, a 
feature cytokine of the T-helper subtype 17 (Th17) which have been associated to tissue 
damage also at intestine level, to be positively associated with score in subjects reporting 
gastric problems (r=0.280, p=0.010). Intriguingly, we detected also a positive relationship 
between BDNF and score of ergonomic dysfunction at the workplace (r=0.284, p=0.009), 
potentially as a result of compensatory protective mechanisms. Taken together, our results 
support the hypothesis that chronic stress induces suppression of both cellular and 
humoral response. However, the consequences are hard to predict since stress is known 
to have both suppressive and enhancing effects on immune system. 
To further explore the potential protective role of BDNF in chronic stress conditions, we 
moved to an in-vitro cellular model of cytotoxic stress, consisting in SK-N-BE human 
neuroblastoma cell line treated with cisplatin, a chemotherapeutic drug. We found that 
cisplatin, in particular after 24 of treatment, enhances BDNF production at both 
transcriptional and protein levels. Of note, it induces also an increment in the transduction 
rate of BDNF mRNA transcripts. We hypothesized that BDNF translation induction occurs 
through the activity of Aurora kinase, like what happen for α-Ca2+/calmodulin-dependent 
protein kinase II (αCaMKII) mRNA, as it is a conserved mechanism from Xenopus oocytes 
to synapses of hippocampal neurons. Therefore, by blocking Aurora kinase activity thanks 
to the potent inhibitor PHA-680632, we were expecting to detect a reduction in BDNF 
translation and increased cell mortality as a result of the decreased trophic support. 
Surprisingly, despite an improved cell death only in combination with cisplatin, we 
observed an enhanced BDNF translation induction especially from those transcripts 
containing exon 6, a splice variant of the 5’ untranslated region, which have been already 
observed to be crucial in cytotoxic stress conditions. In conclusion, our results pointed 
toward a BDNF translation induction mechanism that is Aurora kinase independent, at 
least in conditions of cytotoxic stress. Although not investigated, some of these 
mechanisms may include 5’cap-independent recruitment of the translational machinery. 
Furthermore, our observations could have important clinical implications in the use of 
Aurora inhibitors as adjuvant in neuroblastoma treatment as, even if with a cell mortality 
increase, they facilitate the selection of resistant cells that further enhance BDNF 
production. 
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RIASSUNTO 
Lo stress è stato definito come "una risposta specifica del corpo a qualsiasi richiesta non 
specifica (stressor) su di esso". Quando lo stress, reale o percepito, è duraturo o la 
risposta non è appropriata (distress), i cambiamenti fisiologici di breve termine lasciano 
spazio ad alterazioni di lungo termine che possono causare condizioni patologiche, tra cui 
malattie mentali. Secondo questo modello di "carico allostatico", i mediatori primari come 
le catecolamine e gli ormoni steroidei, innescano alterazioni multi-sistemiche su mediatori 
secondari che portano a manifestazioni negative in diversi sistemi corporei, inclusi quello 
nervoso e immunitario. Neurotrofine, in particolare il Brain-Derived Neurotrophic Factor 
(BDNF), e mediatori del sistema immunitario, come citochine e chemochine, sono possibili 
modulatori della risposta allo stress cronico. Pertanto, ci siamo posti l’obiettivo di valutare i 
loro livelli circolanti in soggetti sani in condizioni di stress lavoro-correlato. Prima di ciò, 
poiché la misurazione del BDNF circolante è di grande interesse per la sfera psichiatrica, 
ma soffre per inconsistenze probabilmente a causa della mancanza di procedure standard 
di selezione e valutazione, abbiamo cercato di superare queste limitazioni definendo una 
metodologia standardizzata sia per la raccolta dei campioni che per la misurazione di 
BDNF. Per fare ciò, abbiamo selezioniamo il siero come fluido elettivo per la 
quantificazione di BDNF e, utilizzando sieri di 40 soggetti adulti sani, abbiamo confrontato 
le prestazioni di sei kit di ELISA commerciali specifici per BDNF. Tutti i kit hanno mostrato 
la capacità di misurare il BDNF nel 100% dei campioni e, con una sola eccezione, range  
paragonabili. Tuttavia, essi hanno mostrato variazioni inter-assay molto diverse, dal 5% al 
38%. Tali variazioni, erano superiori a quelle dichiarate dai produttori fatta eccezione per 
un kit, che nel complesso ha mostrato le prestazioni migliori. In aggiunta, l’analisi Dot-blot 
ha rivelato che due kit hanno riconosciuto selettivamente la forma matura di BDNF, mentre 
gli altri hanno reagito anche con il suo precursore, il pro-BDNF. Occorre notare che, 
avendo definito una procedura standardizzata che riduce l'elevata variabilità dovuta ai 
differenti passaggi tecnici nelle fasi pre-analitiche e analitiche, questo studio fornisce la 
base per ottenere una misura affidabile del BDNF nel siero umano, adatto per potenziali 
applicazioni cliniche future. Come accennato, il passo successivo è stato quello di valutare 
il BDNF e i mediatori immunitari circolanti in soggetti con stress lavoro correlato. Abbiamo 
quindi misurato il BDNF e, utilizzando la tecnologia ELISA multiplex, altri 48 analiti tra 
citochine, chemochine e fattori di crescita nel siero di 122 soggetti sani (87 femmine e 35 
maschi). I partecipanti sono stati arruolati tra assistenti sanitari e valutati per lo stress 
lavoro-correlato con scale stress psicofisico e burnout estratte da un questionario di auto-
valutazione standardizzato per il contesto italiano (test Qu-BO). Lo stress psicofisico è 
stato valutato con cinque elementi, vale a dire ansia, disturbi emotivi, gastrointestinali, 
cardiaci e disfunzioni ergonomiche sul posto di lavoro più uno stato generale di stress 
stimato come la media delle cinque dimensioni; il burnout è stato misurato con tre elementi 
adattati dal Maslach Burnout Inventory, nello specifico esaurimento emotivo, 
depersonalizzazione e realizzazione personale. Alti punteggi di score sono associati a 
situazioni di stress cronico elevato, ad eccezione della scala di realizzazione personale. 
Abbiamo individuato che le donne avevano punteggi più elevati rispetto agli uomini per 
tutti gli elementi di stress psicofisico e per lo stato di esaurimento emotivo. Oltre a ciò, 
dopo aver corretto per sesso e indice di massa corporea (IMC), abbiamo cercato di 
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correlare le variabili biologiche con i punteggi delle diverse scale di stress, utilizzando una 
combinazione di analisi univariate (correlazioni parziali) e multivariate (analisi dei minimi 
quadrati e fattoriale), per tener conto delle correlazioni tra analiti. Come risultato, non 
abbiamo trovato alcuna associazione tra le variabili biologiche e lo stato di burnout, 
mentre, d'altra parte, abbiamo rilevato associazioni negative tra elementi dello stress 
psicofisico e alcuni marcatori del pattern di chemochine. In particolare, abbiamo osservato 
che i livelli di MCP-1/CCL2, CTACK/CCL27, RANTES/CCL5 e Eotassina/CCL11 correlano 
negativamente con diverse scale di stress psicofisico quali ansia, problemi gastrici e 
cardiaci e disfunzioni ergonomiche sul posto di lavoro. Inoltre, abbiamo osservato che IL-
17, una citochina caratteristica del sottotipo T-helper 17 (Th17) e associata a danni a 
diversi tessuti, incluso quello intestinale, correla positivamente con alti punteggi in soggetti 
che accusano problemi gastrici (r=0.280, p=0,010). Curiosamente, abbiamo rilevato anche 
una relazione positiva tra BDNF e il punteggio di disfunzione ergonomica sul posto di 
lavoro (r=0.284, p=0,009), potenzialmente a causa di meccanismi di compensazione 
protettivi. Nel loro insieme, i nostri risultati supportano l'ipotesi che lo stress cronico induce 
una generale soppressione sia risposta immunitaria cellulare e umorale. Tuttavia, le 
conseguenze sono difficili da prevedere in quanto lo stress è noto per avere un effetto sia 
soppressivo che stimolante sul sistema immunitario. 
Per esplorare ulteriormente il potenziale ruolo protettivo di BDNF in condizioni di stress 
cronico, a livello cellulare, ci siamo serviti di un modello di stress citotossico in-vitro, 
consistente in una linea di cellule di neuroblastoma umano, le SK-N-BE, trattata con 
cisplatino, un farmaco chemioterapico. Da ciò abbiamo osservato che il cisplatino, in 
particolare dopo 24 di trattamento, aumenta la produzione di BDNF sia a livello 
trascrizionale che proteico. In aggiunta, lo stimolo citotossico dato dal cisplatino aumenta 
anche il tasso di trasduzione BDNF. Abbiamo ipotizzato che l'induzione della traduzione di 
BDNF avvenga attraverso l'attività di Aurora chinasi, come avviene, ad esempio, per la 
chinasi II dipendente da α-Ca2+/calmodulina (αCaMKII), in quanto si tratta di un 
meccanismo conservato a partire dagli ovociti di Xenopus fino a livello delle sinapsi 
neuronali di ippocampo. Pertanto, bloccando l’attività di Aurora chinasi grazie al potente 
inibitore PHA-680.632, ci aspettavamo di osservare una riduzione nella traduzione di 
BDNF e un aumento della mortalità cellulare come risultato del diminuito supporto trofico. 
Sorprendentemente, nonostante un aumento della morte cellulare, ma solo in 
combinazione con cisplatino, abbiamo osservato una maggiore induzione della traduzione 
di BDNF, soprattutto da quei trascritti contenenti in particolare l’esone 6 di BDNF (una 
variante di splicinge della porzione 5’ non tradotta), il cui ruolo è già stato osservato essere 
cruciale in condizioni di stress citotossico. In conclusione, i nostri risultati delineano un 
meccanismo di induzione della traduzione degli mRNA di BDNF potenzialmente 
indipendente da Aurora chinasi, almeno in condizioni di stress citotossico.  Sebbene non 
dimostrato per BDNF, tali meccanismi potrebbero includere il reclutamento dell’unità 
trascrizionale con modalità indipendenti dalla presenza del cap al 5’ non tradotto degli 
mRNA. Le suddette osservazioni potrebbero avere importanti implicazioni cliniche nell'uso 
di inibitori di Aurora come coadiuvanti nel trattamento del neuroblastoma in quanto, 
nonostante inducano un aumento della mortalità, facilitano la selezione di cellule resistenti 
che producono una maggiore quantità di BDNF. 
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1. INTRODUCTION 
 
1.1 History of stress 
From the industrial revolution to nowadays, clinicians have reported an increasing decline 
in mental health. Since the 19th century, the scientific community argued about three 
possible major causes: heredity, interior or environmental toxins and, as it was called later, 
stress. The underlying features crossing those centuries are the major and fast changes 
within the society, as the increased information exchange, spinning market economy and 
the growing demands over the urban individual. This accelerated exchange-rate potentially 
brings up the self-feeling of being inadequate or unable to keep up mentally and 
physically, in line with the challenging environment. A great number of symptoms have 
been described, as well as many diagnoses have been formulated, to justify the discomfort 
in a culture filled of competition, achievement and seek of leadership. Lots of hypotheses 
have been proposed to link the effects of modern society on the susceptible person, 
spanning from evolution biology to sociology fields. Doctors, who attempt to translate 
individual’s response to threats into medical practice, came out with different theories: from 
the overstrain or “fatigue problem”, in which illness process was physiologically seen as a 
reduction of mental and body “energy”, to “neurasthenia”, which essentially bond the 
chronic fatigue to a reduced nerve energy, intended as a slowed down cerebral and body 
activity (Arnetz and Ekman 2006, chapter 1, pp. 3-12).  
Despite the well known influence of psychological states on physical health, a concrete 
physiological investigation had to wait until the early 40s of the past century, thanks to the 
work of Hans Selye (1907-1982) and, later, from other contributors, including Mason, 
Sterling and Eyer, McEwen, Seeman and Wingfield (Rice 2012, chapter 2, pp. 28). 
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1.2 Stress definition and models 
Selye was a pioneer in addressing the physiological changes occurring during the 
response to physical or perceived threats and essentially coined the term “stress” as we 
meant it today. At the beginning, he observed that patients suffering for different traumatic 
or chronic diseases frequently denote common signs or symptoms, like reduced appetite, 
with loss of weight and muscle strength. He marked this phenomenon as the “syndrome of 
just being sick”. In parallel, he demonstrates that rodents subjected to different noxious 
stimuli like physical, chemical or emotional (extreme hot or cold, blurring lights, formalin, or 
perpetual frustration) all exhibited the same pathologic changes including adrenal gland 
hypertrophy, lymphoid tissue shrinkage and gastrointestinal ulcers. In the long term, these 
animals were also likely to develop some diseases seen in humans, including hearts 
attack, kidney problems and rheumatoid arthritis. These observations let him to define the 
stress as “a nonspecific response of the body to any demand made on it” (Selye 1936), 
and designate stressor as the stimulus causing the stress response (although the term 
stress often designates both the stimulus and the response). Following criticisms of being 
too ambiguous, he later refines the definition of stress as “a state manifested by a specific 
syndrome which consists of all the nonspecifically induced changes within the biological 
system” (Selye 1976, pp. 64). Therefore, this syndrome seems to reflect an extreme 
reaction of the body’s defence to stressors. At a systemic level the entire stress process 
was defined as the General Adaptation Syndrome (GAS), including the threat and the 
individual's reaction to it. The Local Adaptation Syndrome (LAS) was instead referred to 
the regional response (e.g., localized inflammation where microbes have entered the 
body). Combining together all these observation and findings, the GAS and LAS are seen 
as closely coordinated, with the GAS acting as backup (Selye, 1976; Rice 2012, chapter 2, 
pp.24-25).  
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1.2.1 General Adaptation Syndrome (GAS) 
About GAS, Selye wrote: general “because it was produced only by agents which have a 
general effect upon large portions of the body,” adaptive “because it stimulated defence 
and, thereby, helped in the acquisition and maintenance of a state of inurement,” and syn- 
drome “because its individual manifestations are coordinated and, even partly, dependent 
upon one another” (Selye, 1976, pp. 38; Rice 2012, chapter 2, pp. 24). 
The GAS model brought the airy conception of stress into a suitable manner for the 
scientific inquiry. This theory recognizes two main actors of the autonomic nervous 
system, the sympatho-adrenergic-noradrenergic (SAN) and the limbic-hypothalamo-
pituitary-adrenal (L-HPA) systems (which will be discussed later); furthermore, it identifies 
three distinct time phases of the stress response (see figure 1.1): 
• Alarm phase: initiate whenever there is a difference between a set state (or “wish 
state”) and the actual state of a variable; is the first response when an insult 
exceeds the range of “normal” resistance or homeostasis. It corresponds to the 
fight-or-flight reaction described by Cannon (1932) (West, 2010) and is 
physiologically driven by a general activation of the autonomic nervous system, 
which causes increased heart rate and respiration, blood pressure, arousal and 
alertness.  
• Resistant stage: is the phase where a full resistance to the stressor has been 
established and the alarm phase is diminished. Body systems and tissues 
adaptation occur in order to maintain a high level of functioning despite the 
presence of the stressor. 
• Exhaustion phase: the resistant phase cannot be maintained indefinitely and, if the 
organism is unable to return to a normal resistance level (pre-alarm phase) or the 
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stressor is uncontainable, the exhaustion stage occurs. Human resources have 
been depleted and permanent damage of the body systems are likely to occur. 
 
Figure 1.1 Phases of the stress response; from (Carlson, 2007). 
 
The general opinion about stress is usually negative but the stress response is a 
physiological reaction that is essential for survival and has been maintained throughout the 
evolution. Stress cannot be avoided because is part of life, but there are both “good” and 
“bad” stressors. Even winning a lottery or a passionate kiss can evoke a stress response, 
but of course they are not the same as being stuck at work for an important meeting. 
Therefore, Selye attempted to discern between healthy stress, denoted as eustress, and 
pathogenic stress, specified as distress (Tache, J., & Selye, H. 1985).  
  
1.2.2 Allostatic Load Model (AL) 
One of the major criticisms to Selye’s work, made by later contributors, is that GAS model 
does not contemplate perception, cognition and interpretation of the stressor stimulus. The 
work of Mason (Mason, 1971), Sterling and Eyer (1988), McEwen (McEwen, 1998a, 
2000a) and McEwen and Wingfield (McEwen and Wingfield, 2003), overcome this lack 
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with the formulation of the allostasis and allostatic load theories (Rice 2012, chapter 2, pp. 
28). Allostasis refers to the process whereby an organism maintains physiological stability 
by changing parameters of its internal milieu by matching them appropriately to 
environmental demands (Sterling and Eyer, 1988). It emphasizes the ability to maintain the 
equilibrium of the body’s parameters over a dynamic range of set-points, rather than static 
as in homeostasis. Additionally, it reconsiders the central role of the brain in acting as a 
feedback and views the health as whole brain-body ability to adapt to the contexts (Figure 
1.2).  
 
Figure 1.2 The allostic load model; from (McEwen, 1998a; McEwen and Gianaros, 2011). 
 
In the short run, allostasis response is essential for survival and adaptation to adversities; 
it represents the basis of the resilience (Juster et al., 2010; Lupien et al., 2009; McEwen, 
2013) of an individual, in analogy with the property of a material to elastically deform upon 
loading and get back to its original shape when unloaded. However, in the long term, when 
prolonged stressors chronically induce allostasis responses, it causes the body systems to 
overload, driving the so called allostatic load. This represents the “wear and tear” of the 
body, which can accelerate disease processes (McEwen and Stellar, 1993). Keeping 
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parallel with physics, it resembles the break up point of a material. Likewise, as different 
materials have different resilience properties and break up points, allostasis and allostatic 
load mechanisms are different for each individual. Indeed diverse constitutional (genetics, 
development, experience), behavioral (coping and health habits), and historical 
(trauma/abuse, major life events, stressful environments) factors could influence these 
processes (McEwen, 1998a, b). Is worthy of note that threat or stressors can be either real 
or apparent and is their perception and interpretation that triggers allostatic responses. 
Discernment of what is, or is perceived, stressful and what is not is entirely personal and 
largely depend on the above factors as well. Despite the heterogeneity in stressors 
perception and factors that influence allostasis mechanisms, allostatic load model 
identifies general features in the alteration processes driven by chronic stress (see figure 
1.3) (Juster et al., 2010; McEwen, 1998a, 2000a; McEwen and Seeman, 1999): 
• Primary mediators: as already seen in GAS model, the first biological systems 
activated in stress response are the sympathetic–adrenal–medullary (SAM) and the 
hypothalamic–pituitary–adrenal (HPA) axis. The release of catecholamines and 
glucocorticoids, respectively, mobilizes energy necessary for fight-or-flight reaction 
(Sapolsky et al., 2000). While adaptive in acute responses, prolonged secretion of 
stress hormones and their antagonist, along with other humoral mediators, fails to 
protect the distressed person and starts to injure its brain and body. 
• Secondary outcomes: primary mediators exert direct compensation at cellular levels 
and, in turns, in different biological systems, causing a shift in their operative ranges 
in order to maintain functional stability. All these effects compromise the integrity of 
allostatic mechanisms and cause metabolic, cardiovascular, neuroendocrine and 
immune parameters to reach sub-clinical levels. 
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•  Tertiary outcomes: the deregulations got in secondary outcomes potentially 
culminate with an allostatic overload, with disorders or disease or even fatal 
endpoints. 
 
Figure 1.3 Alteraration processes driven by chronic stress, according to the allostatic load model. 
 
An essential aspect of the AL model is that multiple mediators involved in allostasis and 
allostatic overload mechanisms are interconnected in a complex and non-linear network 
(Figure 1.4); thereby, the compensation processes over time and, secondly, the steps in 
the deregulation route happen in a non-linear fashion, so are particularly hard to predict 
(Juster et al., 2010; McEwen and Gianaros, 2011). Nonetheless, the AL model proposes 
that study multi-systemic interaction, along with the identification of sub-clinically relevant 
biomarkers, triangulated with other measurement (genetic, psychological, social 
assessments, etc.), could help in detect individuals at high risk of tertiary outcomes 
(McEwen, 2000a). 
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Figure 1.4 Non-linear network of mediators of allostasis involved in the stress response; adapted from 
(McEwen, 2006). 
 
Numerous studies have been conducted incorporating the AL algorithm in attempting to 
describe the effects of chronic stress from different life aspects: post traumatic stress 
disorders (Glover, 2006); stress in neonatal intensive care unit parents (Mackley et al., 
2010); recovery from colorectal surgery (Slater, 2010); open heart surgery experiences for 
patients and their caregivers (Robley et al., 2010); mother of cancer patients (Glover et al., 
2008); successful aging (Gruenewald et al., 2006; Karlamangla et al., 2006; Seeman et al., 
2004; Seeman et al., 1997b); violence and women’s health (Symes et al., 2010). 
Also the job stress in relation to allostatic load has been investigated: German school 
teachers and industrial workers (Bellingrath et al., 2009; Fischer et al., 2009; Schnorpfeil et 
al., 2003); Dutch telecom managers (Langelaan et al., 2007); Chinese industrial workers 
(Li et al., 2007, Sun et al., 2007); Swedish public health care workers (von Thiele et al., 
2006). 
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Chronic stress typically account for how adverse work environments contribute to disease 
trajectories (Taylor et al., 1997). The job-related chronic stress is of increasing interest in 
both public opinion and scientific community. It has started to being monitored and formally 
regulated in different American (Occupational Safety & Health Administration directives 
from U.S. Department of Labor) end European countries, including Italy, as part of a 
general health framework. 
 
1.3 Job-related stress management: European and Italian policies.  
The consequences of the job-related chronic stress have drawn significant attention since 
the beginning of this century. Almost 22% of the European workers experience job stress 
(Milczarek et al., 2009), which is the cause of nearly 60% of work absences. Due to health 
problems, a European worker stays off approximately four and half days per year (Parent-
Thirion et al., 2007), with women and dependent workers as the most affected categories. 
Overall, in 2002, job stress had cost to Europe roughly 20 million of Euros (Milczarek et al., 
2009). Also in Italy, a study over the Veneto country in 2005, pointed out that 27% of 
workers suffers for stress response related symptoms (Mastrangelo et al., 2008). 
Many recommendations have been proposed to promote the monitoring of job stress 
related warning signs. The European Union is committed to promoting the health and 
safety of workers, so has recognized the work-related stress as an emerging occupational 
health risk which deserves identification, prevention and management like other work-
related risks, in accordance to the principles and methods which underpin EU occupational 
health and safety policy. In this view, on date 8 October 2004 was signed the Framework 
Agreement On Work-Related Stress (Brussels, 24/02/2011) whose aim are twofold: 1) 
increase the awareness and understanding of employers, workers and their 
representatives concerning work-related stress; 2) focalize their attention to 
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symptoms/signs that could reflect problems due to work-related stress. As reported in the 
agreement, stress is recognized as a state, accompanied by dysfunction (physical, 
psychological or social), which results “from individuals feeling unable to bridge a gap with 
the requirements or expectations placed on them”. A subject can cope well with short-term 
stress, but has greater difficulty to deal with prolonged exposure. It also highlight the fact 
that different subject cope differently with similar situations; in addition, different reaction to 
similar situations, at different times in life, can be observed within the same individual. 
While not necessarily spread over all workplaces, the stress can potentially affect any 
worker, irrespectively of size of the company, the field of activity and the contract form. As 
a result, the agreement underlie that “tackling stress at work can lead to greater efficiency 
and improved occupational health and safety”. 
In concrete terms, the agreement points out three important elements: 1) identify problems 
of work related stress; 2) take action to prevent, eliminate or reduce these problems; 3) 
both employers and workers have responsibilities on this topic. This last point, in 
particular, fits in the framework directive 89/391 in which “all employers have a legal 
obligation to protect the occupational safety and health of workers and this responsibility 
also applies to problems of work-related stress”; on the other hand, “all workers have a 
general duty to comply with protective measures determined by the employer”. 
In Italy, the text of the European agreement was implemented, in an almost literal 
translation, during the revision of the occupational health and safety legislation and 
included in the Article 28, paragraph 1 of the Legislative Decree of 9/04/2008 n. 81 
(Ordinary supplement to n. 108/L of Gazzetta Ufficiale n.101 of 30/04/2008). The text 
provides indication on how to identifies job-stress risk factors: 1- negative spot events 
(absenteeism, high turnover, interpersonal conflicts); 2- problems in organization and 
processes (working time arrangements, degree of autonomy, match between skills and job 
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requirements, workload); 3- working conditions and environment (exposure to abusive 
behaviour, noise, heat, dangerous substances, etc.); 4- communication (uncertainty about 
what is expected at work, employment prospects, or forthcoming change, etc.); 5- 
subjective factors (emotional and social pressures, feeling unable to cope, perceived lack 
of support, etc.). All the above indications have been adopted in March 2010 in an 
operational guide by the National Institute for Occupational Safety and Prevention 
(ISPESL). In addition to preliminary evaluation (points 1 to 4), the guidelines imply 
adequate corrective actions and, eventually, a deep evaluation on subjective perception of 
the risk factors (point 5). The proposed methodology emphasizes the necessity to adopt 
both subjective and objective techniques to evaluate workers for job-related stress, during 
the risk assessment process, since integrating as many information as possible would be 
helpful in the proper management of the stress. A detailed discussion of the possible self-
assessed or objective indicators is beyond the scope of the present work, although in later 
paragraphs will be discussed potential applications of physiological measurements as part 
of the objective evaluation of work-related chronic stress. At first, however, there will be an 
overview of the physiology of the stress response, in both allostasis and allostatic load 
mechanisms. 
 
1.4 Physiology of the stress response 
As identified in both General Adaptation Syndrome (GAS) and Allostatic Load (AL) 
models, the main actors of response to stress are the sympatho-adrenergic-medullary 
(SAM) and the limbic-hypothalamo-pituitary-adrenal (L-HPA) systems. These systems are 
interconnected and influence each other activity (Chrousos et al., 1988). Stress biology 
also includes different brain areas involved in implementation of the appropriate adaptive 
response. In brief, sensory inputs, triggered by physical or perceived sensations, 
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communicate information to their specific thalamus area, which act as a relay station and 
transmit them to sensory cortex and amygdala (Amiragova, 1985; Pezzone et al., 1992). 
The sensory cortex in turn communicates either directly or via the hippocampus with the 
lateral amygdala through the perirhinal cortex (Davis and Murphey, 1994; Davis et al., 
1994; LeDoux, 1995). Amygdala is a complex structure, made of several nuclei, which 
receives and integrates signals from cortices, thalamus, locus ceruleus and hippocampus 
and then retransmit over different brain areas as well. This entire signalling network 
converges in activating the sympathetic division of the autonomics nervous system (SAS) 
and in stimulating the paraventricular nucleus of the hypothalamus (PVN) (Petrov et al., 
1994; Ziegler and Herman, 2002). SAS activity, through the action of catecholamines 
(norepinephrine and epinephrine), is responsible for the cardiovascular effects: increased 
heart rate and force of contraction, dilated blood vessel in skeletal muscles while 
constricted in gastrointestinal organs and dilated bronchioles, along with other effects over 
various organs (increased renin secretion, sweat secretion, peristalsis inhibition) (Dunser 
and Hasibeder, 2009). The PVN is an essential structure because receives various inputs 
indicative of stress and modulate the activity of the hypothalamus-pituitary-adrenal (HPA) 
axis (Swanson and Sawchenko, 1983). The HPA response starts from the production of 
the corticotropin releasing hormone (CRH), by PVN neurons, which is then released into 
the hypophyseal portal blood and reaches the anterior pituitary gland. CRH then regulate 
the transcription of the proopiomelanocortin (POMC) gene, a common precursor for the 
adrenocorticotropin hormone (ACTH), and promotes the release of ACTH in the 
bloodstream. ACTH, in turns, induces the synthesis and secretion into systemic circulation 
of glucocorticoids (mainly cortisol in humans, corticosterone in rodents), by the zona 
fasciculata layer of the adrenal cortex (Charmandari et al., 2005; Smith and Vale, 2006). 
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Glucocorticoids are the final effectors of the HPA axis. Their effects are mediated by two 
intracellular receptor types: the mineral corticoid receptor (MR) and the glucocorticoid 
receptor type (GR), which act as ligand-dependent-transcription factors and are distributed 
throughout the body systems. GRs have lower affinity for corticosterone than MRs but 
have a wider distribution in different brain areas, including pre-frontal cortex and PVN; 
MRs are less abundant, but are present especially in some brain structures like the 
hippocampus. Due to different affinity, GRs are predominantly available for binding during 
high level of circulating cortisol, so during stressful situations (Finsterwald and Alberini, 
2014; Reul et al., 1987). The primary effect of glucocorticoids is to promote conversion of 
protein and lipid in usable carbohydrates (McEwen, 2000a) and act on the brain to 
increase appetite and locomotor activity in a food seeking oriented manner (Leibowitz and 
Hoebel, 1997, chapter 15, pp.313-358); overall, they regulate behaviours which control 
energy input and expenditure. Of course, glucocorticoids also play a key regulatory role, 
by switching off the stress response at the end of the stimulus, thus exerting negative 
feedback at different sites (especially pituitary, hypothalamic and some supra-
hypothalamic structures) to inhibit their own release (Figure 1.5). 
The primary stress mediators, glucocorticoids and catecholamines, are protective of the 
individual, in the short run, as they are essential for the reaction to dangerous or life 
threatening situations (Wamsteeker Cusulin et al., 2013). However during chronic stress 
situations, repeated activation or altered negative feedback turns them to wield damaging 
effects (Hyman, 2009; Mizoguchi et al., 2003; van der Laan et al., 2009; Varghese and 
Brown, 2001). It is a sort of cost that body pays for alertness.  
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Figure 1.5 The hypothalamus-pituitary-adrenal (HPA) axis in stress response; from (Hyman, 2009). 
 
1.5 Pathophysiology of stress 
Normally, an increased activity of the stress response system, after an acute stressor, is 
followed by a recovery period back to the steady state level. According to the allostatic 
load model (AL), allostatic overload occurs when the normal response is impaired; this 
could happen through four types of allostatic load mechanisms (figure 1.6): 
• Repeated hits over times: the physiological stress response is challenged many 
times by new stressors. 
• Lack of adaptation: reduced acclimatization to the same kind of stressor. 
• Prolonged response: as a result of a delay in switch off the response (impaired 
negative feedback). 
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• Inadequate response: insufficient reaction of the stress system that drive 
compensatory hyperactivity of other mediators. 
 
Figure 1.6 Four types of allostatic load .See text for description; from (McEwen, 2007). 
 
Whatever the allostatic load mechanism, repeated call-up of primary mediators during 
chronic stress causes primary effects throughout the body system (increased blood 
pressure, heart rate, glucose mobilization, etc.), directly influencing cellular activities. Over 
time, they can cause compensatory mechanisms in secondary mediators, leading to 
secondary outcomes (metabolic alterations, brain plasticity, immune hypo- or hyper-
activity, etc.). This prodromal stage is the forerunner of possible tertiary outcomes, 
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consisting in hastened age-related decline or even actual illnesses (cardiovascular 
disease, depression, cancer, allergic problems, etc.).  
The key concept, previously mentioned, is that all mediators are interconnected in a 
complex network: each mediator system produces biphasic effects and is regulated by 
other mediators, often in reciprocal fashion, leading to non-linear effects upon many organ 
systems of the body (McEwen, 1998a, 2007). Primary mediators consist essentially in 
catecholamines and glucocorticoids and their antagonists, along with cytokines influence. 
Secondary mediators include, among others, metabolic hormones such as insulin, insulin-
like growth factor 1 (IGF-1), leptin and grelin, cholesterol, gonadal hormones, cytokines, as 
well as neurological mediators like neurotrophins (Lu et al., 2006; McEwen, 2007; Pulford 
and Ishii, 2001). Although a comprehensive description of mediators is beyond the scope 
of the Thesis some examples will be further discussed regarding their effect on different 
body systems, focusing on consequences on brain, immune functions and their interaction. 
 
1.5.1 Cardiovascular effects 
 As catecholamines increase blood pressure and heart rate, repeated activation of the 
sympathetic system, due to chronic stress, causes recurrent rise and drop of blood 
pressure which is a factor risk, along with high cholesterol levels, for the formation of 
atherosclerotic plaques. At the same time, as glucocorticoids promotes food seeking 
behaviour, their elevation coupled with a lack of energy expenditure obstruct insulin activity 
in glucose uptake. As a result, insulin level increases and, in combination with 
glucocorticoids, promotes the deposition of both body fat and atherosclerotic plaques in 
the coronary arteries (Brindley and Rolland, 1989; McEwen, 2000a; Vanitallie, 2002). In 
turn, co-occurrence with smoking, drinking and reduced physical activity greatly enhances 
the risk of cardiovascular disease, such ischemia and stroke, or myocardial infarction. 
17 
 
 1.5.2 Brain effects 
Brain is both the mediator and target of the stress response. Is the perception and 
interpretation of a situation that decides what is stressful or not. Strong emotions impact 
especially on the activity of pre-frontal cortex, amygdala and hippocampus, which aid to 
remember the circumstances that turn them in such a powerful manner. The aim is to 
increase awareness or avoidance for similar situations that may happen in future. 
However, chronic stress can imbalance this mechanism toward an exaggerated state 
which lead to anxiety conditions or mental illness (Leuner and Shors, 2013). The reasons 
of this negative shift are due, at least in part, in changes in neurochemical balance and 
alteration in dendritic and synaptic structures on neurons within the specified brain regions.  
Hippocampus, which is one of the most implied structures in the pathophysiology and 
treatment of mood disorders, is the most flexible and malleable brain structure as it is 
involved in both memory acquiring and modulation of the SAM and HPA axis. It expresses 
both glucorticoid receptors (GRs and MRs) and adrenal hormones exert a biphasic effect 
on excitability of hippocampal neurons in terms of long-term potentiation and primed burst 
potentiation (Diamond et al., 1992; Pavlides et al., 1995) and show parallel biphasic effects 
upon memory (McEwen, 2007). The regulation of glutamatergic transmission, by 
glucocorticoids (Karst et al., 2005), required MRs through a mechanisms that involves 
glucocorticoid enhancement of extracellular levels of glutamate (Venero and Borrell, 
1999), playing an important role in both modulatory and excitotoxic effects of 
glucocorticoids. In fact, adrenalectomy prevents stress-induced rise of extracellular 
glutamate (Lowy et al., 1993), while corticosterone infusion recapitulates these effects in 
absence of stress. According to Sapolsky’s glucocorticoid cascade hypothesis, chronic 
glucocorticoid administration or repeated stress downregulate hippocampal steroid 
receptors, but not hypothalamic or pituitary receptors (Sapolsky et al., 1986) and display 
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decreased sensitivity to glucocorticoid fast feedback (Herman et al., 2012; Young and 
Vazquez, 1996). As a general feature, chronic stress tends to induce dendritic retraction 
and reduced branching of neurons, as shown in chronic restrain rats. Pyramidal neurons in 
area CA3 are particularly affected, although pyramidal neurons in area CA1 and granule 
neurons in the dentate gyrus can be similarly influenced (Magarinos et al., 1996; Vyas et 
al., 2002; Watanabe et al., 1992). Also changing in spine morphology and spine loss has 
been observed during chronic stress, although the type and magnitude of these effects 
seem to vary across hippocampal subregions (McLaughlin et al., 2009; Mucha et al., 
2011). Not only excitability and dentritic remodelling are affected, but also neurogenesis 
and neuron survival are impaired, as both are reduced in chronic stress.  
The mechanisms through which stress induces hippocampal changes include a plethora of 
other mediators, as neither adrenal size nor steroids levels, nor presumed amount of 
psychosocial stress, per se, determined dentritic remodelling (McEwen, 1999, 2007); (see 
Figure 1.7). These includes excess of glutamate via NMDA receptors activity (Magarinos 
and McEwen, 1995), enhanced serotonergic tone (McKittrick et al., 2000) as well as 
altered inhibitory tone from interneurons and GABA (Cullinan et al., 2008). Metabolic 
factors involved in glucose regulation further have an impact in hippocampal changes, as 
also a diet rich in fat impairs hippocampal dependent memory. Furthermore, tissue 
plasminogen activator (tPA), which is an extracellular protease and signalling molecule 
that is released with neural activity, is involved in chronic stress-induced loss of spines and 
NMDA receptor subunits on CA1 neurons (Pawlak et al., 2005). Repeated stress in 
rodents results in reduced expression of transmembrane glycoprotein M6a, which is 
associated with a decreased in filopodia number and synaptophysin expression. 
Interestingly, these effects are prevented by antidepressant treatment with tianeptine 
(Kuroda and McEwen, 1998). Another important factor is the CRH, which is not only an 
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inductor of ACTH production, since it is produced also by GABA hippocampal 
interneurons. While in acute stress low doses enhance memory processes, presumed high 
level during chronic stress results in spine retraction and loss of synapses (Chen et al., 
2012). In addition, the brain-derived neurotrophic factor (BDNF), which is the most 
abundant neurotrophin in CNS, is known to play a role in dendritic and spine plasticity; its 
involvement in chronic stress effects will be further anlyzed in the text. Ultimately, the 
neuronal cytoskeleton undergoes structural reorganization processes, with changes in 
actin and microtubule architecture concomitantly with alterations in dendrites or spines in 
the hippocampus (and other regions), induced by stress through intracellular mechanisms. 
(Jaworski et al., 2009; Penzes and Rafalovich, 2012). 
 
Figure 1.7. Neural cells system involved in stress dendritic remodelling; from (McEwen, 2007). 
 
As demonstrated by chronic restrain paradigm in rats, dentritic atrophy and spine loss 
occurs also in medial prefrontal cortex (mPFC) in a similar fashion of what observed in 
hippocampus. However, effects display a high degree of sexual dimorphism: males are 
more affected to dentritic shrinkage during stress than women (Radley et al., 2006). In 
addition, chronic stress interacts with aging to influence mPFC plasticity by a structural 
point of view. While rats of all ages showed stress-induced dendritic retraction, these 
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effects are reversible after a stress-free recovery period in young rats, but are irreversible 
in aged rats (Bloss et al., 2010). 
The amygdala pyramidal and stellate nuerons, in contrast to the hippocampus and mPFC, 
exhibit hypertrophy after repeated stress events in a regionally specific manner. In detail, 
chronic stress enhances dendritic length, branch points, spine number, and spine length 
on neurons of the BLA without altering these measures in the central nucleus of the 
amygdala (Vyas et al., 2003). Interestingly, these hypertrophic changes persist even after 
a period of recovery from stress (Vyas et al., 2004). 
Usually hippocampus, amygdala and prefrontal cortex structures are investigated 
separately. Nevertheless, as they are heavily interconnected and influence each other, 
their circuitry, as a whole, seems to be impaired during chronic stress, although further 
investigations are needed on this way. For example, the induction of LTP in the 
"hippocampus-mPFC pathway" connection is impaired by stress (Cerqueira et al., 2007; 
Mailliet et al., 2008) as well as in the pathway from the amygdala to the mPFC (Maroun 
and Richter-Levin, 2003). Moreover, by the reduction of hippocampal structure, stress may 
diminish activity in hippocampal afferents to the mPFC which could in turn reflect to fewer 
mPFC dendritic spines (Leuner and Shors, 2013).  
The take home message is that chronic stress mediators can induce transitory or lasting 
changes in neuron morphology and activity (Joels et al., 2007). The types of alterations 
are region specific and could differentially impact circuitry functions; moreover they may 
herald anxiety and depression states or other mental illness. 
 
1.5.3 Immune effects 
There are two kind of immunity, natural and specific. The natural immunity is a fast 
(minutes to hours) and aspecific response against antigens, mediated by complements 
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proteins, natural killer cells and by cells of the granulocyte/macrophage lineage (including 
monocyte/macrophages and neutrophils). The typical response mounted by these cells is 
inflammation, as they get onto the site of infection and release radical oxygen species and 
other toxic substances that damage both invaders and tissue. Macrophages, in particular, 
have an important regulatory function in orchestrating the inflammation response, through 
production of immune mediators, cytokines and chemokines. Differently, the specific 
immunity is characterized by greater specificity but less speed, because it requires antigen 
recognition and clonal expansion, so it takes many days until full defence has been 
mounted. The actors of this response are the three major classes of lymphocytes, namely 
T-cytotoxic, B cells and T-helper cells. Usually, the first class drives the so called cellular 
response, which is against intracellular pathogens (for example viruses, but also tumoral 
cells), while B-cells mount a humoral immunity, producing antibodies against extracellular 
pathogens. It’s important to note that also innate immune actors participate to both cellular 
and humoral responses. T-helper cells exert important regulatory functions by producing 
immune mediators, playing at the interface of humoral, cellular and natural immunity 
(Segerstrom and Miller, 2004). Classically, the T-helper 1 (Th1) and 2 (Th2) sub-
populations act by coordinating effector functions of either macrophages and cytotoxic T 
cells or B cells, respectively (Mosmann and Coffman, 1989). However the situation is 
much more complex as new kind of T-helper, specifically Th17 and Treg, have been 
described and display mainly inflammatory and anti-inflammatory properties, respectively 
(Steinman, 2007).  
Nervous and immune systems are known to interact and influence each other activity 
(Besedovsky and Sorkin, 1977). The huge body of findings describing their relationship 
have created a new field known as "psychoneuroimmunology". Both systems share 
common mediators and receptors: immune cells express receptors for catecholamines and 
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glucocorticoids as well neurons have receptors for immune mediators. These include the 
aforementioned cytokines and chemokines, which are soluble molecules produced either 
peripherally by lymphocytes and granulocytes or centrally by microglia and astrocytes and 
operate within a complex network, acting either synergistically or antagonistically (Reiche 
et al., 2004). But how chronic stress may impact the immune system? In general, 
catecholamines increase proinflammatory cytokine production (Bierhaus et al., 2003) while 
glucocorticoids are known to reduce inflammation (Sapolsky et al., 2000). However there 
are great exceptions, as glucocorticoids and catecholamines exhibit both inflammatory and 
anti-inflammatory properties in a dose and cell dependent manner (Dinkel et al., 2003; 
MacPherson et al., 2005). Also the parasympathetic nervous system may play a regulatory 
role in this context, since it generally opposes the SA, having potential anti-inflammatory 
effects (Borovikova et al., 2000). It has been shown that chronic stress can have both 
immunosuppressive and immunostimulating effects. How this paradox can be explained? 
The most accepted model hypothesizes a decreased ratio in the Th1/Th2 balance, 
resulting in an enhanced humoral immunity but suppressed cellular mediated response. A 
possible mechanism is that primary stress mediators reduce production of interleukin-12 
(IL-12) by cells of the innate immunity and naive T helper, limiting the differentiation toward 
Th1-cells (mainly producers of γ-interferon (IFN-γ) and tumor necrosis factor α and β 
(TNF-α, TNF-β)). On the other hand, cytokine pattern for Th2 differentiation (including IL-4 
and IL-10) seems unaffected by neuroendocrine mediators, thus shifting toward a humoral 
response (Reiche et al., 2004). Yet, the picture is far from being so simple, as also Th17 
and Treg greatly contribute to modulate the effects of Th1 and Th2. The presence of β-
transforming growth factor (TGF-β), IL-6 and IL-23, which shares a subunit with IL-12, 
induce the proliferation of Th17 cells, while the absence of IL-6 pushes toward a Treg 
phenotype. Th17 and Treg subpopulations appear to antagonize each other, despite they 
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are both IL-17 producers and its overproduction as been associated to tissue damage. 
There is also evidence of reciprocal function of Th1 and Th17, as IFN-γ is a Th17 
suppressor, despite TNF-α counteracts this effect. Additionally, Th2 cells antagonize Th17 
because of IL-4 production (Steinman, 2007). 
These observations evidence the high degree of redundancy and pleiotropism of immune 
mediators, suggesting that is often required more than the action of a single cytokine to 
influence the fate and function of T helper cells, as well as other immune cells. Being said 
that, the T-helper unbalance during chronic stress, causes two overall different effects: the 
suppression of cellular specific immunity has been associated with increased vulnerability 
to intracellular pathogens (i.e. viruses) and tumour progression, giving the well known 
roles of T cytotoxic lymphocytes in recognize and suppress infected or cancer cells. On 
the other hand, the over activation of humoral response has been related to 
hypersensitivity disease such as allergies, rheumatoid arthritis and gastrointestinal 
problems, due to activation of B-lymphocytes and other adjuvant cells (eosinophils, mast 
cells, neutrophils) following recognition of auto-antigens thus driving self-tissues 
destruction (Segerstrom and Miller, 2004). Also natural-killer (NK) cells and Th17 have 
been shown to participate to tissue damage, while Treg activity inhibits autoimmunity and 
protects against tissue injury (Bettelli et al., 2006). The influence on innate immunity is 
potentially a mixed effect, as innate immune effectors are partners of both cellular and 
humoral responses (Figure 1.8). 
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Figure 1.8. Systemic effects of glucorticoids, epinephrine and norepinephrine on the immune system (from 
Reiche 2004). 
 
The cytokines IL-1, IL-6 and TNF-α, mainly produced by monocytes/macrophages, are 
classically associated with inflammation as they are major players during the acute phase 
response. They act locally, promoting migration of leukocytes from the blood stream to the 
site of infection (TNF and IL-6 promotes the expression of vascular-cellular adhesion 
molecules (VCAM-1) and intercellular adhesion molecules (ICAM-1), respectively) (Chen 
et al., 2006a; Yednock et al., 1992), and also centrally, promoting fever, appetite 
suppression and stimulation of CRH production (thus increasing HPA activity). However, 
they have a recognized activity of both promoting and inhibiting the inflammation. For 
example, while anti-TNF therapy has proven efficacy against rheumatoid arthritis and 
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Crohn disease, treatment with TNF or IL-6 ameliorate the phenotype of animal model with 
experimental allergic encephalomyelitis (Di Marco et al., 2001; Steinman, 2007). 
Beside cytokines, also chemokines, which are a family of smaller protein (8 to 12 kDa), are 
involved in cellular migration and intercellular communication. Since both ligands and 
receptors (G-protein coupled) are widely distributed in different brain areas (as 
hippocampus, hypothalamus and cortex), some authors have started viewing chemokines 
as a third major system of communication in the brain, along with neurotransmitters and 
neuropeptides (Adler et al., 2005). 
Cytokines and chemokines can influence the central nervous system by two means: 1) 
they are produced centrally by glia (microglia cell in particular, which are macrophages 
equivalent) and astrocytes; 2) they are produced peripherally and reach the CNS via blood 
stream. Usually, they do not cross the blood-brain barrier (BBB), but in some occasion 
they do, as evidenced by the presence of saturable transport systems, which have been 
found for IL-1β, IL-6 and TNF-α (Banks, 2005; Gutierrez et al., 1993). Neuroinflammation 
has been described to sustain disease progression in Alzheimer, Parkinson and Multiple 
Sclerosis, so has been hypothesized to play a role also in depression (Glass et al., 2010; 
Nolan et al., 2013; Postal and Appenzeller, 2015), which can be considered one of the 
ultimate manifestations (tertiary outcome) of chronic psychological stress. Concerning the 
relationship between psychological stress and inflammation, researchers came out with 
conflicting results: some reported a broad inflammation status (Hansel et al., 2010; 
Schmidt et al., 2010), while others found a general immune suppression (Calcagni and 
Elenkov, 2006; Dhabhar et al., 2012; Kawamura et al., 2001; Lucas et al., 2007). As 
already discussed, chronic stress can induce both, depending on the type of stressor, its 
time frame and the psychophysical status of the individual. In addition, concerning the 
function of cytokines and chemokines, categorization such as “pro-inflammatory” or “anti-
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inflammatory” should be taken cautiously as their effect depend on: tissue localization and 
cell type involved; concomitant presence or absence of other immune modulators (dose-
dependence); type of receptor engaged and ultimately its downstream pathways 
(Dhabhar, 2009). Finally, these apparently contradictory results highlight the complexity of 
interactions between brain and immune system, either in physiological or allostatic 
conditions. 
As mentioned, the described systems are not the solely involved and affected in the 
response to chronic stress and all the body systems participate in a coordinated manner. 
This justify the non-sequential steps cascade that result in allostatic overload and how 
hard is to define the causalities of events that lead to disease manifestations like 
cardiovascular incidents, mental illness, hypersensitivity disease and cancers.   
The above considerations emphasize the involvement of other physical and psychosocial 
variables. These, for instance sex, disease state, behaviour and social status, will be 
briefly discussed in the next paragraph.  
 
1.6 Determinants in chronic stress response and stress management 
The brain is both a target and a mediator of the allostatic load occurring in chronic stress. 
It decides what is stressful and how to cope and the reaction further influences its activity. 
The degree of stress perception, the type of responses and their effects on body, along 
with the probability to arise allostatic overload (tertiary outcomes) are individual and largely 
depend on four broad categories of factors: constitutional, behavioural, historical and 
socio-environmental. Albeit an exhaustive description is beyond the scope, some of the 
variables are briefly depicted below, as they worth to be mentioned. 
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Constitutional:  
• Gender: ovarian steroids contribute to a variety of neurochemical processes, 
inducing gender differences in cognition, emotional and affective styles, pain and 
psychopathology. MRI studies show activation of different brain areas during stress 
(Wang et al., 2007). Female have in general a higher risk to develop allostatic 
overload (Bellingrath et al., 2009; Juster et al., 2010). 
• Age: as age increases, the likelihood of tertiary outcomes tends to raise (McEwen, 
2000b).  
• Genetic factors: the allele T of the angiotensin-1 converting enzyme (ACE, 
rs4968591) has been related to a higher risk of allostatic load. (Smith et al., 2009). 
Another example is the short form of serotonin transporter which is associated to 
higher risk of alcoholism (Herman et al., 2005) and vulnerability in the response to 
stressful experiences, by developing depressive illness (Caspi et al., 2003). 
Additionally, having the Val66Met polymorphism of the BDNF gene is associated 
with reduced hippocampal volume, impaired memory and mood disorders (Baj et 
al., 2013a; Chen et al., 2006b; Spencer et al., 2010). 
• Personality: type A personality traits (highly ambitious, organized and status 
conscious individuals; Friedman and Schustack 2010) are related to higher risk of 
coronary heart disease and allostatic overload (Sun et al. 2007). 
Behavioural: 
• Substance dependence: smoking by an effort-reward imbalance interacts with age 
lowering bone-marrow derived progenitor, therefore wakening vascular integrity 
(Fischer et al., 2009; Siegrist et al., 2004). Consequently, smoke is associated to 
increased risk of cardiovascular disease and cancer. Surprisingly, alcohol intakes 
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inversely correlate with allostatic load risk (Hu et al., 2007); however, alcohol abuse 
has a long term negative impact on metabolic and cognitive status (Mukamal et al., 
2010). 
• Food intake: hypothalamus and hippocampus interaction is involved to control food 
intake; stress often leads to eat “comfort food” (Dallman et al., 2003) which in turn 
has been linked to metabolic risk and obesity.  
• Sleep: sleep deprivation, which is a frequent result of being “stressed”, has a 
plethora of consequences on body systems; negatively impacts the neuroendocrine 
circadian rhythm, increases blood pressure, decreases the parasympathetic tone, 
and promotes appetite (McEwen, 2006; Spiegel et al., 1999). Reduced sleep has 
also a negative impact on the immune system, as sleep facilitates T-cell 
extravasation and redistribution to lymph node and enhances the formation of 
immunological memory (Besedovsky et al., 2012). 
• Physical activity: A sedentary life-style is a major risk factor for many of the 
diseases of modern life including obesity, diabetes, cardiovascular disease, 
depression, and dementia. Moderate, but not intense, physical activity improves 
metabolic and cognitive scores. In this sense, it has an anti-depressant effect and 
increases hippocampal neurotrophin expression (BDNF in particular) as well as 
stimulates neurogenesis from the dentate gyrus of the hippocampus (Baj et al., 
2012; Krogh et al., 2014; Olson et al., 2006). 
Historical: 
• Early life experiences: they have effects on human physiology and behaviour. “Bad” 
experiences negatively influence the ability to cope with future stressful situations. 
In animal models, poor maternal care leads to a “neophobic” phenotype with 
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increased emotional and HPA reactivity and less exploration of a novel situation 
(Lajud and Torner, 2015; McEwen, 2008). It also induces hyppocampal dysfunction 
and cognitive impairment, which involves also excessive activation of the CRH 
receptors (Ivy et al., 2010). In humans, the likelihood of poor mental and physical 
health in adults is increased by childhood experiences in emotionally cold families 
(Brown et al., 2005; Repetti et al., 2002). Moreover abuse in childhood is a well-
known risk factor for depression, posttraumatic stress disorder, idiopathic chronic 
pain disorders, substance abuse, antisocial behaviour, as well as obesity, diabetes, 
and cardiovascular disease (Anda et al., 2006; Brown and Heimberg, 2001). 
• Trauma: life traumas increase the probability risk for anxiety-related disorders such 
as post-traumatic stress disorders and are associated with reduced hippocampal 
volume and HPA axis impairment (Cohen et al., 2006; Gorka et al., 2014). 
• Co-morbidities: the concomitant presence of other disturbances such as 
cardiovascular problems, cancers or dementia, negatively impacts on the ability to 
react to new or prolonged stressors. 
Socio-environmental: 
• socioeconomical status (SES): low education and income are collectively 
associated with increased prevalence of several disease such osteoarthritis, 
hypertension, as well predict substance abuse and anxiety and mood disorders. 
Similarly, living in poor conditions (dirty or polluted environment) increases the risk 
of allostatic load. More in general, SES is an effective predictor of health status 
(McEwen and Gianaros, 2010; Seeman et al., 2010). 
• Ethnicity and spirituality: ethnicity interacts with socioeconomical status as poor 
Caucasian were less likely than non-poor African Americans to have increased risk 
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of allostatic overload (Geronimus et al., 2006; Merkin et al., 2009). Positive life 
outlook, high-self esteem, sense of purpose and religious attendance all contribute 
to the proper management of stressful situations (Juster et al., 2010). 
• Relationships (family, work, social support): interpersonal relationships in all social 
contexts can bias an individual towards either a positive or negative response in a 
new situation (Tugade and Fredrickson, 2004). 
The described factors not only influence the response to chronic stress but are part of a 
general framework of healthiness and successful aging. The brain is a malleable structure 
that is “shaped” by life events, as it changes structurally and functionally in order to adapt 
to situations. Stressful events do not necessarily damage the brain but can be long-lasting, 
so proper intervention (when possible) on variables that influence their consequences 
would be beneficial in stress management but also could ameliorate life quality. Some of 
the interventions should include government policies that improve community service and 
personal opportunities and encourage healthy life-styles. More in general social support, in 
term of having positive relationships with familiars, friends and colleagues in professional 
context, has beneficial effects on mood and overall mental health (Leskela et al., 2006; 
Saxena et al., 2006; Silver et al., 2006). 
Moreover, changes in personal behaviour and clearing out “bad habits” have shown to 
give optimal results in term of successful aging and decreased risk of allostatic overload 
manifestations. Dietary restrictions possibly combined to voluntary moderate exercise 
have been shown to be beneficial for metabolic, cardiovascular and brain systems. They 
result in reduced risks of obesity, diabetes, cardiovascular disease and also lowered 
probability of dementia and depression. In brain these factors, specifically in hippocampus 
and cortex, have been shown to increase dendritic arborisation, spine density and 
improved learning in hippocampal-dependent memory tasks (Baj et al., 2012; Cotman and 
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Berchtold, 2002). Similar results have been obtained following antidepressant drugs 
treatment, potentially explaining the antidepressant effect of physical exercise. These 
effects have been related to increase expression of neurotrophins in these areas, in 
particular BDNF, as it is the major central neurotrophin.  
At last, if social and behavioural improvements do not suffice, pharmaceutical treatments 
may provide useful support. For example, anti-glycolic, anti-cholesterol and beta blockers 
can be used to control metabolic and cardiovascular problems; similarly, anxio-lytics and 
antidepressant may control mood manifestations of being “stressed”. Anyway, the usage 
of any drug must be carefully monitored, because of the non-linearity of allostasis systems: 
it may not be beneficial for the systems in question or even perturb other systems that 
interact with it, promoting unwanted side effects. 
 
1.7 Neurotrophins and stress: the role of BDNF  
The growth, differentiation and survival of neurons are supported by specific growth 
factors, known as neurotrophic factors (NT). NTs are four small secreted proteins that play 
important roles in the development of the nervous system in vertebrates (Chao et al., 
2006). In particular the NGF superfamily includes, brain-derived neurotrophic factor 
(BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5) and 
neurotrophin-6 (NT-6). NTs bind with specific affinities to transmembrane-receptors 
belonging to a small family of tropomyosin-related tyrosine kinases (Trk): TrkA (NGF), 
TrkB (BDNF and NT-4), and TrkC (NT-3) (Huang and Reichardt, 2003). Trks are receptor 
tyrosine kinases that dimerize upon ligand binding which converges in their activation and 
subsequent initiation of several signal transduction cascades. In addition, the pro-NTs form 
can also bind to the p75 neurotrophin receptor (p75NTR) with an equal affinity, mediating 
apoptosis or cell cycle arrest. A good control of the development and function of the 
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neuronal cells is given by the possibility, for the same neurotrophin, to bind different 
receptors. Among NTs, BDNF is of particular interest because is the most abundant 
neurotrophin of central nervous system. Like other NTs, is synthesized predominantly by 
neurons in an activity-dependent manner and released upon neuronal depolarization 
(Cirulli and Alleva, 2009). The binding between BDNF and TrkB receptor, induces the 
dimerization and autophosphorilation of the receptor itself which in turn activates three 
different signaling pathways: the mitogen-activated protein kinase (MAPK), the 
phosphatidyl-inositol 3-kinase (PI3K) and the phospholipase C (PLC) (Li and Pozzo-Miller, 
2014). Each of these pathways influence different BDNF actions: MAPK pathway 
promotes neuronal differentiation, PI3K pathway is involved into the regulation of 
transcription favouring survival and growth of neurons, while PLC pathway controls ion 
channel effects in promoting synaptic plasticity (Dwivedi, 2012; Mattson and Wan, 2008; 
Yoshii and Constantine-Paton, 2010). For this reason, BDNF has different roles in 
neuronal cells. During the development of nervous system it contributes to dendritic and 
axonal growth (Yoshii and Constantine-Paton, 2010), then in mature neurons it is involved 
in neuronal homeostasis, cell survival and death and synaptic plasticity (spine formation 
and maturation, long terminal potentiation and long terminal depression) (Poo, 2001). 
BDNF is also crucial for learning and memory processes (Lu et al., 2008; Yamada et al., 
2002). 
Due to the described functions, several data suggest that reduced BDNF signalling in the 
adult brain, as well other NTs, may be implicated in the pathophysiology of the mental 
consequences of chronic stress, as it is a risk factor for psychiatric disorders, such as 
depression (Altar, 1999; Duman and Monteggia, 2006; Rothman and Mattson, 2013). 
BDNF itself does not control mood, but it plays an important functional role in the 
modulation of networks which ultimately determine how a plastic change influences mood 
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(Castren et al., 2007; Sen et al., 2008). Stabilization of axonal and dendritic branches and 
strengthening of synaptic connection are driven by BDNF-TrkB bound in an activity 
dependent manner, so both BDNF release and TrkB receptor expression must take place, 
in a coordinated fashion, at the relevant synaptic sites for the optimal synaptic response to 
occur. 
On this basis, these neurotrophic factors play a fundamental role in shaping brain function. 
Consequently a pathological alteration in NTs concentration or action early during 
postnatal life could exert long-term effects on synaptic plasticity, for example impairing the 
ability of the organism to cope with novel/stressful situation, leading to psychopathology 
(Zubin and Spring, 1977). The importance of (early) developmental influences in the 
etiology of psychiatric disorders, such as depression, has been recognized, but has been 
often under-emphasized. Early life stressful events, such as childhood trauma and neglect, 
are associated with depression and anxiety disorders and sustained changes in the HPA 
axis (Heim and Nemeroff, 1999, 2001). Numerous data suggest that NT-mediated 
neuronal plasticity is a critical factor in mood disorders and in their therapy.  The 
synergistic action between alterations in neurotrophin levels, as a result of exposure to 
stressful events at adulthood and epigenetic changes, caused by early stress, could lead 
to greater susceptibility for stress-related psychiatric disorders (Cirulli et al., 2009). The 
negative consequence of chronic stress on mood, memory and cognition, has been 
associated to a reduction in hippocampal volume, due to dendritic shrinkage and decrease 
neurogenesis, and they can be account, at least in part, by a reduction in BDNF level or its 
activity. A consistent number of findings support this hypothesis. In human, smaller 
hippocampal volumes and memory dysfunction have been associated with a single 
nucleotide polymorphism (SNP) (Val66Met) of the BDNF gene (Baj et al., 2013a; Cirulli 
and Alleva, 2009). This finding has been confirmed also in animal models in which the 
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reduced availability of BDNF, experimentally induced by the Met/Met gene variant, 
enhances anxiety-related behaviour; interestingly, these are reversed after BDNF 
treatment. As already introduced, the effect of stress on hippocampal structure and activity 
depends on the type of stressor, its duration and the time frame when it occurs. Early life 
stress paradigm in rodents, like maternal deprivation or maternal separation, has been 
associated with disruptions in later cognitive and emotional functioning of the animal 
improving potent and long lasting effects on neurotrophin expression levels (Bath et al., 
2013; Romeo et al., 2003). In fact, many authors found a general decrease in BDNF 
mRNA and protein levels and sometimes a decreased expression of TrkB receptors in the 
hippocampus, effects that are more pronounced when early stressed rodents reach 
adulthood (Lee et al., 2012; Lippmann et al., 2007). Similar outcomes were obtained also 
using paradigms of later life stressors such as social defeat or isolation, acute (that 
induces BDNF increase) or chronic restrain, footshock/unpredictable stress, but results 
display a higher variability that can be account, in part, as a difficult to disentangle the 
contribution of pain or the lack of clear controls. Additionally, some groups have failed to 
find any changes in BDNF levels following repeated restraint stress (Kuroda and McEwen, 
1998; Magarinos et al., 2011; Rosenbrock et al., 2005), and others have suggested 
transient reduction of BDNF levels in the hippocampus (Bath et al., 2013; 
Lakshminarasimhan and Chattarji, 2012). It should be noted that most of the studies were 
done on male rats and some of the stress paradigms effect on hippocampal BDNF levels, 
shows high degree of sexual dimorphism: in particular, maternal deprivation reduces 
BDNF only in male rats, while repeated (but not acute) footshocks negatively affect BDNF 
levels only in female. Interestingly, peripheral administration of BDNF in male mice 
increases hippocampal neurogenesis and reduces anxiety-related behaviour induced by 
chronic unpredictable stress, novelty-induced hypophagia, forced swim test and elevated 
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plus maze (Schmidt and Duman, 2010). Hippocampal BDNF reduction was also prevented 
by antidepressant treatment (Lee and Kim, 2010) and physical exercise (Baj et al., 2012; 
Papathanassoglou et al., 2014). Overall, data suggest BDNF decrease as a common 
aspect of chronic stress effects and mood disorders. However, this is not entirely true, at 
least not for all brain areas. For example, the same chronic immobilization stress insults 
that cause BDNF reduction and dendritic atrophy in the CA3 region of the hippocampus, 
cause an increase in BDNF levels, growth of dendrite and spines in basolateral amygdala 
(BLA); furthermore, unlike CA3 atrophy, BLA hypertrophy persist even after 21 days of 
stress-free recovery (Lakshminarasimhan and Chattarji, 2012). In addition, increased 
BDNF in PVN and pituitary gland enhances the expression of CRH and ACTH, 
respectively, having so a positive feedback on HPA-axis activity. Notably, BDNF-TrkB 
signalling is essential for fear conditioning in the circuitry connecting PVN and central 
amygdala (CeL): as a result, selective deletion of either BDNF in the PVN or Trkb in CeL 
neurons impaired fear conditioning, while infusion of BDNF into the CeL enhances fear 
learning and elicits unconditioned fear responses.  
The open question is how much of the rodent findings can be translated to humans. 
Reduced hippocampal volume has been found in depressed patients, depending also on 
the duration of depressive symptoms (Videbech and Ravnkilde, 2004). Concerning BDNF, 
it can be detected in both plasma and serum, and a close relationship between brain and 
peripheral BDNF levels has been identified. The main hypothesis that needs to be tested 
is whether changes in BDNF levels following stress could reflect ‘‘allostatic” processes 
activated to coordinate brain and body responses to specific external challenges (Cirulli 
and Alleva, 2009). In a Japanese population of job-related stress workers (Mitoma et al., 
2008) was found a negative correlation between serum BDNF and the stress score. Lower 
serum BDNF was found also in depressed patients, probably as a result of lowered 
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release from platelet unrelated to platelet reactivity (Karege et al., 2005). In some cases, 
as found in rodents, serum BDNF level can be reverted by antidepressant treatment 
(Matrisciano et al., 2009) or moderate physical activity. Also others disorders, including 
schizophrenia (Carlino et al., 2011; Zhang et al., 2012), bipolar disorder (Machado-Vieira 
et al., 2007), eating disorders such as bulimia nervosa and anorexia nervosa (Mercader et 
al., 2007) or Huntington’s disease (Ciammola et al., 2007; Zuccato et al., 2011) are 
characterized by reduced serum and plasma BDNF levels. However, findings are a bit 
controversial, as some authors find no change or even an increase in BDNF expression in 
depressed subjects (Pigatto Teche et al., 2013) and no effect on BDNF levels wielded by 
antidepressant therapy. It should be noted that circulating BDNF is not produced only 
centrally but also by many cell types, including endocrine and endothelial cells, myocites, 
adipocytes and immune cells. BDNF exerts immunomodulatory effects as well, as it is 
involved in T- and B-cell maturation in an autocrine manner. Similarly, BDNF and TrkB 
receptor are upregulated in activated macrophages (Barouch et al., 2001). Moreover TrkB 
density negatively correlates with the apoptotic rate of cytotoxic T cells (De Santi et al., 
2009). Notably, an elevated concentration of BDNF was found also in atherosclerotic 
plaques. In addition, there is a plethora of other demographic and behavioural variables 
(Bus et al., 2011), such as sex, smoking and drinking habits, physical exercise and dietary 
practice, which can influence the level of circulating BDNF, and account for some of the 
inconsistencies found in literature. Nevertheless, many of these discrepancies are due to 
different methodology for collection and analysis of circulating BDNF, since standardized 
methodologies at both pre-analytical and analytical stages are still lacking. Addressing this 
topic is mandatory for future studies assessing BDNF in blood. 
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1.8 Allostatic load measurement: the biomarker potential  
The allostatic load theory implies the possibility that studying the alterations in the 
allostasis mechanisms during chronic stress, and how the parameters change in relation to 
them, would aid in identify individuals at high risk of disease outcome. Any disease-
associated changes that can be reliable measured in tissue or body fluids are referred as 
biomarkers (Drucker and Krapfenbauer, 2013). Many studies applying the allostatic load 
model have included also the assessment of potential biomarkers as indicator of risky 
changes in the major physiological systems involved: metabolic, 
cardiovascular/respiratory, neuroendocrine and immune. For example, metabolic 
measurements like glucose, total cholesterol, triglycerides and cardiovascular assessment 
as systolic/diastolic pressures and hear rate are used to determine the risk of metabolic 
syndrome or cardiovascular disease. Notably, in older-middle aged adult, the prediction of 
occurrence of cardiovascular problems and, surprisingly cognitive outcomes, is supported 
by metabolic markers detection, while both metabolic syndrome and neuroendocrine 
biomarkers accounted for mortality risk and only marginally to physical decline (Juster et 
al., 2010). Measurement of cytokines like TNF-α, IL-1, IL-6, C-reactive protein (CRP) and 
coagulation factors are largely used to assess inflammatory status. Neuroendocrine 
biomarkers include, for example, cortisol, adrenaline and noradrenalin: increased cortisol 
level accounts most to memory impairment in women (Seeman et al., 1997a; Seeman et 
al., 1997b), while increased adrenalin correlates to cognitive decline in men (Karlamangla 
et al., 2005). It appears, however, that primary mediators contribute independently to 
cardiovascular and metabolic risk factors in predicting cognitive and physical functioning 
declines (Karlamangla et al., 2002). Furthermore, these studies highlight the advantage of 
incorporating multi-systemic biomarkers, although specific clusters seem to predict tertiary 
outcomes differentially. 
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Due to the non linear network that connects physiological systems together and the non-
sequential steps that lead to tertiary outcomes, the associations between diseases and 
large sets of biomarkers are hugely challenging (Poste, 2011). On one side, the low 
specificity may provide some insight into the high rates of co-morbidity that exists between 
many disorders. On the other hand, most of the inconsistencies in biomarker research 
come from the high variability between individuals, but also due to lack in standardized 
practice for specimen sampling and analysis. This, in particular, is one of the most 
important problems in finding specific and reliable biomarkers, as also make difficult to 
compare studies on similar topics. 
The aforementioned difficulties are particularly evident in the context of psychiatry 
biomarkers. In fact, the availability of biomarkers to support the diagnosis or monitor the 
efficacy of therapies is a major unmet clinical need in neuropsychiatry. As already stated, 
the neurotrophin Brain-Derived Neurotrophic Factor (BDNF) is one of the most promising 
biomarkers in psychiatry; however a definitive clinical validation is still lacking. Meta-
analyses and reviews of clinical studies based on the measurement of BDNF in whole 
blood, serum, or plasma have reported significantly lower BDNF levels in patients with 
major depression, schizophrenia, bipolar disorders, or autism spectrum disorders (Katoh-
Semba et al., 2007). These reviews, however, highlighted severe discrepancies among 
studies which even report opposed results (increase vs. decrease or no change). On this 
basis an accurate measurement is a fundamental pre-requisite in order to validate any 
biomarker for neuropsychiatric diseases (Drucker and Krapfenbauer, 2013).  
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2. AIMS OF THE PROJECT 
 
The aims of the present Thesis are three-fold: 
1) Proper specimen collection, handling and analysis are essential in order to identify any 
biomarker in a reliable way. This is a predominant problem concerning biological 
psychiatry, where availability of biomarker is a major unmet clinical need. Brain-Derived 
Neurotrophic Factor (BDNF) has attracted increasing interest as a potential biomarker to 
support the diagnosis or monitor the efficacy of therapies in neuropsychiatry. However, a 
current major limitation to the use of BDNF as clinical biomarker is the poor reproducibility 
of results. We hypothesized that a major source of inconsistencies among studies could be 
the variety of methods for sample collection and BDNF analysis. To overcome these 
limitations, we selected the serum as the elective body fluid for BDNF quantification and 
defined a standardized method to prepare the samples for BDNF quantification. Then, 
using serum samples from 40 healthy adult subjects, we compared the performance of six 
commercial BDNF ELISA kits from the companies: Aviscera-Bioscience, Biosensis, 
Millipore (ELISA and Luminex®/xMAP® multiplexing technology), Promega and R&D 
Systems, to identify the most performing one in BDNF assessment. 
2) We then analyzed BDNF levels and other 49 distinct cytokines, chemokines and growth 
factor in the sera of 122 healthy subjects among healthcare assistance; the goal is to find 
a potential correlation between immune factors and scores assessing psychophysical job-
related stressors and burnout. 
3) Using a cellular model of cytotoxic stress, given by the SK-N-BE neuroblastoma cells 
treated with the chemotherapic cisplatin, we address the potential protective role of BDNF. 
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3. MATERIAL AND METHODS 
 
3.1 AIM 1 
 
3.1.1 Participants and sample collection 
Forty healthy subjects (mean age 54±6, range: 41-70 years old; 18/22 Females/Males 
ratio) participated in this study as normal controls. Subjects were enrolled at the 
Department of Transfusion Medicine of the Trieste University Hospital and signed written 
informed consent to participate to the study, according to the recommendations of the 
declaration of Helsinki and the Italian DL n° 675 o f the 31-12-1996. The study was 
approved by the University Hospital's Ethics Committee (protocol n. 78/2010). Blood 
samples from healthy control subjects were collected between 9:00 to12:30, in fasting 
condition and let them clot for 1 hour at room temperature, followed by 1 hour at 4°C. 
Serum was then separated by centrifugation at 2000 g for 10 minutes at 4°C, aliquoted 
and stored at -80°C until use in 0.2 ml tubes strip s (Starstedt, Multiply® µStripPro).  
 
3.1.2 BDNF measurement 
Serum levels of total BDNF were measured by using six different ELISA kits, as listed in 
Table 2: human BDNF ELISA Kit (Cat #: SK00752-01, Aviscera-Bioscience, Santa Clara, 
CA, USA), BDNF RapidTM ELISA Kit: Human, Mouse, Rat (2 Plates; Cat #: BEK-2211-2P, 
Biosensis Pty Ltd., SA, Australia), ChemKineTM BDNF Sandwich ELISA (Cat #: CYT306) 
and Milliplex® Map Human Pituitary Magnetic Bead Panel 2 - Endocrine Multiplex Assay, 
based on Luminex®/xMAP® technology (Cat #: HPTP2MAG-66K, both from EMD Millipore 
Corporation, Billerica, MA, USA), BDNF Emax® Immuno-Assay System (Cat #: G7610, 
Promega Corporation, Madison, WI, USA), Quantikine® human BDNF Immunoassay (Cat 
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#: DBD00, R&D Systems, Inc., Minneapolis, MN, USA). All samples were assayed in 
duplicate on each plate, in order to test also the intra-assay variation. A number of two 
plates per kit were used over two different days in order to assess the inter-assay 
variation. Protocols were performed according to the manufacturer’s instructions. The 
optical density of each well was measured using an automated microplate reader 
(GloMax®-Multi Microplate Reader, Promega) or the Bio-Plex®-200 instrument (Bio-Rad) 
for the multiplexing assay measurements. 
 
3.1.3 Statistical analyses 
For each kit, sensitivity and range were estimated based on the standard curves. 
Sensitivity was stated as equal to the kit declared value if the absorbance of the most 
diluted standard point was 10% over the background (blank absorbance). Similarly, range 
was confirmed equal to the declared one if the inclusion of the most concentrated standard 
point did not reduce the R2 (linearity of the curve) below the 90%. Because BDNF values 
were not normally distributed, data are presented as median, 25th-75th percentile and 
range (see Table 5). Differences in BDNF serum level from the six kits were tested using 
one-way analysis of variance (ANOVA) followed by the post hoc Dunnett test. To evaluate 
intra-assay variation, the BDNF values from the two different well, for each subject, were 
mediated and the coefficient of variation (CV) was calculated for all samples. Again, due to 
the non-normal distribution of the CVs, the median value was considered. Similarly, to 
assess inter-assay variation, the BDNF concentrations, for each subject, were mediated 
between the two plates tested and the median CV value was considered. Differences in 
the BDNF concentrations, as a repeated measure from two independent plates, were 
assessed using one-way ANOVA for repeated measures. Values of p<0.05 were 
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considered statistically significant. All statistical analysis and graphs were performed using 
SigmaPlot 11.0 (Systat Sofware, Inc.). 
 
3.1.4 Dot blot 
Commercially available human recombinant pro-BDNF (Alomone Labs) and two type of 
mature-BDNF (Sigma and Alomone Labs) were spotted on a nitrocellulose membrane at 
the concentration of 10 pg and 1000 pg per lane, respectively. Together, were spotted 
BSA (1000 pg), as negative control, and the BDNF standards (between 25 pg and 100 pg, 
depending on the stock concentration) provided by the ELISA kits. Dot-blots were 
performed according to Abcam guidelines with minor modifications, and all steps were 
carried out at room temperature. Briefly, once proteins have been spotted, the membrane 
strips were dried and then non-specific sites were blocked by soaking in 5% BSA in TBS-T 
(20 mM Tris-HCl, 150 mM NaCl, 0.05% Tween20) for 30 minutes. ELISA’s primary 
antibodies were used at the concentrations suggested by each kit manufacturer in the 
diluents provided, when possible; Millipore (ChemikineTM) and Promega antibodies were 
dissolved in BSA/TBS-T (0.1% of BSA in TBS-T). Monoclonal antibody anti-BDNF (Sigma) 
was used as control at a dilution from stock to 1:1000 in 0.1% BSA in TBS-T. All 
incubations with primary antibodies were performed for 1 hour and then strips were 
washed three times in TBS-T for five minutes each. As secondary detector, streptavidine-
HRP was used (Pierce Biotechnology; 1:2000 in BSA/TBS-T), except for Promega 
polyclonal antibody (the anti-IgY-HRP provided with the kit was used) and for Promega 
and anti-BDNF (Sigma) monoclonal antibodies (the anti-mouse-HRP from Sigma was 
used, diluted 1:10000 in BSA/TBS-T). R&D System antibody is already HRP-conjugated 
and did not require further detection by a secondary antibody. Incubations were performed 
for 30 minutes, followed by three wash steps with TBS-T and then rinsed with TBS. As 
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reaction substrate, ECL-prime (Amersham) was used and X-ray film exposed in the dark 
room to display the signals. 
 
 
3.2 AIM 2 
 
3.2.1 Participants  
The study was performed examining a sample of workers in an Italian healthcare 
organization. Workers were informed beforehand by management and participated 
voluntarily to the study. Workers completed a self-report questionnaire aimed at 
determining work-related psychophysical stress and burnout state. The questionnaire was 
completed by 122 subjects who agreed to participate to a clinical interview followed by a 
blood sample withdrawal. Blood samples were collected and sera isolated as previously 
described in Aim 1. Subjects reporting mood and anxiety disorders, neuroendocrine 
diseases, non-pharmaceutical drug abuse or dependence, according to DSM-IV-TR 
criteria, were excluded from the enrollment. Therefore, the study sample comprised 122 
workers, of which 71.3% were women, with a mean age of 45.6 years (SD = 9.6). For the 
work position, 16.7% were managers-doctors, 63.3% were doctors or head nurses, 20% 
were nurses. Most respondents had a permanent contract (95.9%). All participants gave 
their written, informed consent, and the study was approved by the local ethic committee 
according to the recommendations of the declaration of Helsinki. 
 
3.2.2 Work-related stress assessments 
Subjects were assessed for psychophysical stress and burnout state determined using five 
and three items, respectively, taken from the Qu-BO test, an instrument standardized for 
the Italian context (Falco et al., 2012). The six point response scale ranged from 1 
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(strongly disagree) to 6 (strongly agree) and is designed to behave as a continuous scale. 
For psychophysical stress the items assessed are the following: anxiety, emotion 
(depression-like), gastrointestinal disturbances, cardiac disturbances, ergonomic 
dysfunction at the workplace. The overall stress score was estimated by averaging the 
scores of each item. For burnout, the items are the following: emotional exhaustion, 
depersonalization, personal accomplishment, adapted from the Maslak Burnout Inventory 
(Maslach et al., 2001). The scores were calculated by summarizing the questions 
describing each item. 
 
3.2.3 Biochemical assessments 
Collected serum was stored at -80°C until assayed. Multiple analytes were assessed, as 
listed in Table 1.  
 
 Cytokines Chemokines Trophic factors 
21-plex 
(BioRad) 
IL-1α; IL-2Rα; IL-3; IL-12 (p40); 
IL-16; IL-18; IFN-α2; LIF; MIF; 
SCF; TNF-β; TRAIL/TNFSF10 
CTACK/CCL27; GRO-α/CXCL1; 
MCP-3/CCL7; MIG/CXCL9;  
SDF-1α/CXCL12; 
HGF; M-CSF/CSF1; 
β-NGF; SCGF-β/CLC11 
27-plex 
(BioRad) 
IL-1β; IL-1Ra; IL-2; IL-4; IL-5; 
IL-6; IL-9; IL-10; IL-12 (p70); IL-
13; IL-15; IL-17; IFN-γ; TNF-α; 
GM-CSF 
IL-8/CXCL8; Eotaxin/CCL11; 
MCP-1/CCL2 (MCAF);  
IP-10/CXCL10; MIP-1α/CCL3; 
MIP-1β/CCL4; RANTES/CCL5; 
IL-7; basic FGF;  
G-CSF; PDGF-BB; 
VEGF  
BDNF 
RapidTM 
ELISA kit 
(Biosensis) 
/ / 
BDNF 
 
Table 1 Biochemical analytes listed by cytokines, chemokines and trophic factors. 
 
Serum BDNF levels were assessed using classical sandwich ELISA, as previously 
described in Aim 1. Cytokines, chemokines and growth factors were measured taking 
advantage of the multiplex ELISA technology, employing the Bio-Plex Pro Human xMAP 
Assay 21-plex and 27-plex (Bio-Rad Laboratories Srl, Milan, Italy) read on a Bio-Plex 200 
instrument, according to manufacturer’s instructions. Reliability of cytokines 
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measurements with this methodology was previously validated (Zanin et al., 2012). All 
samples were assayed in duplicates and the same plate was used. 
 
3.2.4 Statistical analyses 
Work-related stress scores were used as dependent variables, while biochemical analytes 
level as independent variables; gender, age and body mass index (BMI) were treated as 
co-factors. Differences in age and BMI distribution between male and female were 
assessed performing a Mann-Whitney U-test. Likewise, sex differences in distribution of 
work-related stress scores were evaluated using Kruskal-Wallis tests.  
Many biochemical variables had sample values below the lower limit of detection (Out-Of-
Range values or OOR). When OOR values were over the 30% of the total sample, the 
analytes were excluded. For others, we imputed the half of sensitivity value for each 
analyte. The influence of the use of drugs on biochemical values was tested performing 
Kruskal-Wallis tests. Normality distributions of the independent variables were assessed 
by Shapiro-Wilks tests and visually inspected by Quantile-Quantile (Q-Q) plot analyses. 
Since most of the variables were not normally distributed we decided to log-transform 
values in order to approximate normality distributions, thus being able to perform both 
univariate associations and multivariate analyses. 
As univariate analyses, we perform partial correlation analyses controlling for gender and 
BMI to identify association between dependent variables (scores) and each independent 
variable (biochemical markers). Since we performed multiple biomarkers assessment on 
same samples, we chose to not correct for multiple comparisons across the different 
analytes, since this would enhance the probability of type II errors (Janelidze et al., 2013). 
Multivariate analyses were also carried out to take in account for potential correlations 
within the independent variables. Thus, we performed Partial-Least Square discriminant 
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analysis (PLS) and Variable Importance to the Projection (VIP) scores were estimated, for 
each independent variable, as the average over three latent factors extracted. 
Unsupervised analysis of the biochemical markers was also carried out; hence we did a 
Principal Axis Factoring with 30 iterations and the minimum number of latent factors was 
extracted based on the Eigen-value cut-off ≥1. Promax rotation (30 iterations) with Kaiser 
Normalization algorithm was employed to assign variables to latent factors. Correlation 
values below 0.4 were hidden. 
All statistical analyses and graphs were performed by using the SPSS® Statistical Package 
version 22.0 (IBM®). 
 
3.3 AIM 3 
 
3.3.1 Cell cultures and reagents 
Human neuroblastoma cell line SK-N-BE were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) with stable L-Glutammine, 100 U/ml penicillin, 100 µg/ml streptomycin 
and 10% decomplemented fetal bovine serum (FBS) at 37°C with 5% CO 2. Differentiation 
was induced 24 hours after plating by adding 5 µM of 9-cis retinoic acid (Sigma) to cultures 
and replaced after 48 hours. Differentiated cells (4.5 days) were treated with 5 µg/ml 
cisplatin (Pfizer) with or without 10 µM of the Aurora kinase inhibitor PHA-680632 (kindly 
gifted by Fabio Gasparri, Nerviano Medical Science) in serum free medium (SFM).  
 
3.3.2 Real-time PCR for BDNF cds and isoforms quantification 
Total RNA was extracted, using TriZol® Reagent (Invitrogen), from differentiated SK-N-BE 
cells after different hours of cisplatin treatment: one, three, six, twelve and twenty-four 
hours and a non-treated control. One microgram of total RNA was reverse-transcribed into 
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cDNA as previously described (Baj and Tongiorgi, 2009) and employed for a quantitative 
real time PCR (qRT-PCR), performed using the Rotor Gene 6000 instrument according to 
the manufacturer’s instructions. The PCR reactions were carried out in a final volume of 
20µl with 2X Master SYBR Green I Mix (Fluocycle, Euroclone), 0.5 µM of each primer and 
1µl of cDNA was added as template. The qRT-PCR was used to evaluate both total and 
BDNF splice variants expression after cisplatin treatment at the given time points. The 
primer pairs used along with the PCR conditions are listed in Table 2.  
 
Human 
exons 
Sequence Product (ex fwd+com rev) 
PCR conditions  
(ex fwd+com rev) 
exI fwd CTTCCAGCATCTGTTGGGGAGACG 205 45X(95°C 20”,56°C 20”,72 °C45”) 
exII fwd CCAGCGGATTTGTCCGAGGTGG 192-404-487 45X(95°C 20”,56°C 2 0”,72°C45”) 
exIII fwd AGCCCAGTTCCACCAGGTGAG 165 45X(95°C 20”,56°C 20”,72°C45”)  
exIV fwd ACCGAAGTCTTCCCCAGAGCAG 219 45X(95°C 20”,56°C 20”,72°C45 ”) 
exV fwd ACCAATAGCCCCCATGCTCTG 227 45X(95°C 20”,55°C 20”,72°C45 ”) 
exVI fwd TGGAGCCAGAATCGGAACCAC 209-227 45X(95°C 20”,56°C 20”,72°C 45”) 
exVII fwd CCACATCTCTACCCATCCTGC 305 45X(95°C 20”,56°C 20”,72°C4 5”) 
exVIII fwd TGGCATGACTGTGCATCCCAG 253 45X(95°C 20”,56°C 20”,72°C45 ”) 
exIXa fwd ACAATCAGATGGGCCACATG 238 45X(95°C 20”,56°C 20”,72°C45”) 
com rev ACGCTCTCCAGAGTCCCATG / / 
cds fwd AAACATCCGAGGACAAGGTGGC 230 45X(95°C 20”,56°C 20”,72°C45”) 
cds rev GGCACTTGACTACTGAGCATCACC “ “ 
 
Table 2 List of human primers, product size and PCR conditions used for real-time PCR experiments.   
 
3.3.3 ELISA assay for total BDNF detection 
BDNF production in differentiated SK-N-BE neuroblastoma cells was assessed using the 
ELISA BDNF Emax® Immuno-Assay System (Promega Corporation, Madison, WI, USA) at 
the same time points evaluated in real-time PCR. Briefly, cells in treated and control 
conditions, as described above, were lysed and 12.5 µg of total protein were loaded on 
pre-coated wells according to manufacturer’s instructions. 
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3.3.4 Western blotting 
Differentiated SK-N-BE cells were treated, as described above, and lysed on ice in lysis 
buffer [125 mM Tris-HCl pH 7.5, 2% SDS, protease inhibitor cocktail (Sigma)]. Proteins 
were resolved into 12% SDS-PAGE, loading equal volumes (20 µl) of the lysates and 
electroblotted onto nitrocellulose membrane. Membranes were cutted above the 35 KDa 
marker band and differentially processed. The lower parts were blocked with fat-free 5% 
milk in TBS-T (50 mmol/L Tris-HCl pH 8.0, 133 mmol/L NaCl, 0.1% (v/v) Tween-20) and 
then incubated at 4°C in overnight gentle-shaking w ith anti-BDNF N-20 antibody (1:500 in 
TBS-T; Santa Cruz). After three wash steps with TBS-T, the membranes were incubated 1 
hour at room temperature with anti-rabbit HRP-conjugated antibody (1:2000 in TBS-T; 
Dako). The upper part of the membranes were blocked with fat-free 5% milk in PBS-T 
(Phosphate Buffer Saline, 0.1% (v/v) Tween-20), then incubated overnight at 4°C with anti-
αTubulin antibody (1:8000 in blocking solution; Sigma Aldrich); after three washing steps, 
a further incubation of 1 hour at room temperature with anti-mouse HRP-conjugated 
antibody (1:10000 in PBS-T; Sigma) was performed. Thereafter, all the membranes were 
washed three times and developed with ECL Prime (GE Healthcare). Densitometric 
analyses of the western blots were performed using Quantity One software (Bio-Rad), 
according to user manual. 
 
3.3.5 Luciferase assay 
Luciferase assays, aimed to evaluate the translatability capacity of BDNF isoforms, were 
performed as described previously (Vaghi et al., 2014). Briefly, plasmid vectors containing 
5’ UTR exons 1, 2c, 4 or 6 and 3’URT long cloned at the edges of a Firefly luciferase 
(Fluc) reporter were used to test the influence of BDNF UTRs on translatability in 
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stimulated conditions. Around 3000 SK-N-BE cells per well were seeded in 96-well plate 
designed for luminescence assays (BD Falcon) and induced to differentiate, as described. 
Differentiated cells were co-transfected with one of the above construct along with a vector 
containing a renilla (Rluc) reporter as transfection control. Transfection was stopped after 
6 hours by replacing media or starting the 24 hour-point cisplatin treatment with/without 
Aurora kinase inhibitor in SFM. The day after, a 6 hour-point treatment was also performed 
before carrying out the dual-luciferase assay in an automated Glomax plate reader (both 
from Promega), according to manufaturer’s instructions. 
 
3.3.6 Cell-survival analysis 
A colorimetric MTT assay was performed to assess cell survival. 5000 SK-N-BE cells were 
plated in 96-well plates, maintained, let to differentiate then treated, as described in “Real-
Time PCR” paragraph. Viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT from Sigma) following manufacturer’s instructions. 
 
3.3.7 Immunofluorescence and microscopy 
Immunofluorescence on SK-N-BE cells was performed as follow. After fixation in 4% 
paraformaldehyde (PFA) in phosphate-buffer-saline (PBS) for 20 minute at room 
temperature, cells were washed with PBS and permeabilized for 15 minute with PBS-
Triton 0.1% (PBS-T), then blocked with PBS-T and 2% BSA. Thereafter, cells were 
incubated for 2 h at room temperature with primary antibodies diluted 1:50 in blocking 
solution. After three washes in PBS, cells were incubated 1h at room temperature with 
secondary antibodies coupled with Alexa 488 or 568, diluted 1:200 in PBS-T, then wash 
with PBS and stained with Hoechst to mark nuclei. Finally, coverslips were mounted in 
Mowiol antifade compound (Sigma). The following antibodies were employed: Mouse 
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monoclonal anti-BDNF (Sigma); Rabbit polyclonal anti-actin (Sigma); anti-mouse Alexa 
Fluo 488 (Invitrogen); anti-rabbit Alexa Fluo 568 (Invitrogen). 
Images were acquired using a Nikon Eclipse E800 epifluorescence microscope with a 20X 
objective and a Nikon DXM1200 camera, paired with ACT-1 software. Cells were manually 
counted dividing the image in five subfields and averaging the number over three areas 
per coverslip. The number of cells is expressed as relative percentage to untreated 
condition. BDNF spots were counted using ImageJ 1.45b (NIH, Bethesda, USA) and 
expressed over the cell area in µm2. Briefly, images were processed for z-stack projections 
and thresholds were applied to highlight spots and cells area and then analyzed using the 
Analyze Particle tool. All images were processed in the same manner. 
 
3.3.8 Statistical analyses 
All statistical analysis and graphs were performed using SigmaPlot 11.0 (Systat Software, 
Inc.). One-way ANOVAs followed by Holm-Sidak corrections against control were 
performed to compare treated groups against controls in order to determine statistical 
significances, which was set at p<0.05.  
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4. RESULTS 
 
4.1 AIM1- A standardized methodology for human BDNF collection and analysis 
 
As already introduced, BDNF has an attractive potential in aid the diagnosis or monitoring 
therapies of neuropsychiatry disorders; however, inconsistencies between studies have 
prevented its clinical use. Our working hypothesis was that the lack of reproducibility 
described in the literature could be the result of methodological dissimilarities among the 
different studies at the pre-analytical stage (sample preparation and storage), the 
analytical stage (analysis execution) or assay-related (intrinsic assay quality). Therefore, 
we undertook a study aimed at standardizing the methodology to measure BDNF in 
human serum. Accordingly, we first defined a methodology for sample preparation and 
storage and then we measured BDNF concentration in the sera from 40 healthy volunteers 
using 6 different commercial kits and we compared their performance. 
 
4.1.1 Pre-analytical stage 
To standardize the pre-analytical stage, we reviewed the current literature on serum BDNF 
measurement and we evaluated the different methods used for sample preparation and 
conservation (see table 3). Our approach was to identify similarities among the different 
studies and define the confidence intervals of the main technical determinants in each 
step. We first analysed the available literature regarding the patient preparation and the 
effect of fasting or not fasting blood draw condition in adults and children. El-Gharbawy 
and colleagues (El-Gharbawy et al., 2006) reported no difference in BDNF levels between 
fasting and non-fasting children while in adults, non-fasting conditions resulted in 
attenuated BDNF levels (Bus et al., 2011). Hence, our protocol included blood draw from 
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adults in fasting conditions. Concerning the effect of the time of blood withdrawal on BDNF 
levels, data in the literature are controversial. Piccinni (Piccinni et al., 2008) did not 
observe circadian BDNF variation, neither in men nor in women. On the contrary, Bus and 
colleagues (Bus et al., 2011; Bus et al., 2012) reported attenuated BDNF serum level from 
the late morning onward. Giese et al. (Giese et al., 2014) found a reduction trend during 
the day, which was not statistically significant. However, circadian variation in plasma 
BDNF level has been described by many authors (Begliuomini et al., 2008; Choi et al., 
2011), reporting a peak in the early morning and the lowest concentration by the late 
evening. Hence, our protocol included blood withdraw between 8 and 12:00. Concerning 
the clotting time and temperature, there are only few studies taking into account this issue 
as a possible source of variability in the detection of BDNF serum levels. Katoh-Semba et 
al. (Katoh-Semba et al., 2007) stated that at 26°C,  plasma BDNF starts to be degraded 
after 30 min, while it reaches a maximum level at 4°C between 24 h and 42 h after 
collection. On the other hand, Elfving and colleagues (Elfving et al., 2010) found that 
BDNF levels in serum were stable for 24 h at room temperature. A recent work from Giese 
(Giese et al., 2014), established that the mean BDNF concentration is not significantly 
different between 1 and 5 hours of clotting time at room temperature; moreover, for 
samples clotted 1 hour at room temperature, followed by 1 hour at 4°C, the results were 
strictly similar to those obtained after 1 hour at room temperature (Maffioletti et al., 2014). 
Therefore, in order to have more flexibility during preparation of the sera, our protocol 
included 1 hour incubation at room temperature, followed by 1 hour at 4°C. Concerning the 
centrifugation speed, time and temperature, there are no specific data on this topic, 
however, in the majority of the studies, the centrifugation temperature is either at room 
temperature or 4°C, while speed and time ranges are  between 1000-3500 g and 10-20 
minutes, respectively. On this basis, we selected the shortest centrifugation time (10 min) 
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at an intermediate gravity force (2000 g) and, in order to maximize BDNF conservation, we 
performed centrifugation at the temperature of 4°C.  Recent studies highlighted that the 
storage temperature of the sample is a critical issue for BDNF degradation. It has recently 
been demonstrated that samples stored at -20°C show  a significantly lower BDNF 
concentration already after 6-10 months but, if stored at -80°C, the decline is not 
significant up to 5 years (Bus et al., 2011; Trajkovska et al., 2007). In this study, aliquots of 
50 µl serum samples were stored at -80°C in thin wa ll 0.2 ml PCR tubes arranged in strips 
of 8 tubes with attached flat lid (Starstedt, Multiply® µStripPro). 
SERUM 
PREPARATION STEP 
INTERVAL OF 
CONFIDENCE 
CHOSEN 
PROTOCOL REFERENCES 
Patient preparation 
- Preferentially fasting 
condition for adults 
- Indifferent for children  
Adult in fasting 
conditions 
- Bus BAA, 
Psychoneuroendocrinology 
(2011) 36:228—239  
- El-Gharbawy A H, The Journal 
of Clinical Endocrinology & 
Metabolism (2006) 91(9):3548–
3552 
Time of blood withdrawal 
Data are controversial: 
little or no circadian 
variation for serum 
BDNF – possibly a little 
decrease of serum 
BDNF in the afternoon 
9 .00 -12.30 a.m. 
- Bus BAA, The World Journal of 
Biological Psychiatry (2012) 13: 
39–47 
- Bus BAA, 
Psychoneuroendocrinology 
(2011) 36:228—239  
- Begliuomini S, The Journal of 
Endocrinology (2008) 197:429–
435 
- Piccinni A, Chronobiol Int. 
(2008) 25(5):819-26. 
- Katoh-Semba R, Int. J. Devl 
Neuroscience (2007) 25:367–372 
- Choi S-W, Psychiatry Research 
(2011) 186:427–430 
- Giese M, Journal of Psychiatric 
Research 59 (2014) 1-7 
Clotting time and 
temperature 
30 min to 24h, RT 
or 
1h to 42h, 4°C 
1h, RT+ 1h, 4°C 
- Elfving B, Journal of 
Neuroscience Methods 187 
(2010) 73–77 
- Katoh-Semba R, Int. J. Devl 
Neuroscience 25 (2007) 367–372 
- Maffioletti E, BioTechniques 
(2014) 57:111-114 
Centrifugation time, 
speed and temperature 
No specific studies 
- 1000 g to 3500 g 
- 10 min to 20 min 
- 4°C or RT 
2000g x 10 min at 4°C Most of the published data 
Storage temperature - 20°C up to 3-6 months 
- 80°C up to 5 years - 80°C 
- Trajkovska V, Brain Research 
Bulletin (2007) 73:143–149 
-Bus BAA, 
Psychoneuroendocrinology 
(2011) 36:228—239 
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Table 3 Definition of steps protocol for serum preparation to BDNF assessment, based on literature 
comparison. 
 
4.1.2 Analytical stage 
To standardize the analytical stage, we considered five sandwich ELISA assays from 
different companies (Aviscera-Bioscience, Biosensis, Millipore-ChemikineTM, Promega-
Emax® and R&D System-Quantikine®) and one multiplexing assay (Millipore-Milliplex®). 
The main characteristics of the kits and their performance, as declared by the 
manufacturers, are described in Table 4. BDNF concentration was assessed using the six 
kits in the sera prepared from 40 healthy blood donors (mean age 54±6 years; 18/22 
Females/Males ratio). Analysis of BDNF serum concentration was carried out at controlled 
room temperature (24°±1°C) and repeated measures we re carried out by the same 
experimenter using two aliquots of the same sera stored at -80°C and then thawed only 
once at the time of usage. Whenever a positive control and/or an additional point of the 
standard curve were requested by the kit, the samples tested were lowered to 38 
(Aviscera-Bioscience and Millipore-Milliplex®) or 39 (Biosensis). Sample recovery was 
100%, as we always found measurable concentrations of BDNF, irrespectively of the kit 
used. Distributions of values were not normal and therefore data are shown as box plot 
with indicated median value and 10th, 25th, 75th, 90th percentile (Figure 4.1). Serum BDNF 
concentrations resulted to be in the same range for all kits with the exception of Millipore-
ChemikineTM, which showed a significantly lower median value and distribution range 
(p<0.05, ANOVA on ranks; Figure 4.1, Table 5). Median values and percentiles for the 
other five kits were comprised between a minimum of 18.2 (14.2-22-2) to a maximum 25.5 
(21-30.5) ng/ml (not significant, Table 5). 
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Company Aviscera-
Bioscience 
Biosensis Millipore Millipore Promega R&D System 
KIT Name Human BDNF 
ELISA 
BDNF 
RapidTM 
ELISA 
ChemikineTM Milliplex® BDNF Emax® 
Immuno-
Assay 
System 
Quantikine® 
Catalog 
Number 
# SK00752-01 # BEK-2211-
2P 
# CYT306 # HPTP2MAG 
-66K 
# G7610 # DBD00 
Principle of 
the assay 
Sandwich 
ELISA 
Sandwich 
ELISA 
Sandwich 
ELISA 
Luminex®/ 
xMAP® 
technology 
Sandwich 
ELISA 
Sandwich 
ELISA 
Sensitivity 
(pg/ml) 
5-8 2 7.8 2.5 15.6 20 
Range of 
detection 
(pg/ml) 
23-1500 7.8-500 7.8-500 12 - 50000 7.8-500 62.5-4000 
BDNF 
standard 
Human 
recombinant 
1500 pg/vial, 
1 vial 
Human 
recombinant 
1000 pg/vial, 
4 vials 
Human 
recombinant 
10000 pg/vial, 
2 vials 
Mix of BDNF 
12500 pg 
+Prolactin 
25000 pg/vial, 
1 vial 
BDNF 
standard (not 
declared 
type), 1ug/ml, 
50 ul 
Human 
recombinant 
8000 pg/vial, 
3 vials 
Coating/captur
e Antibody 
Pre-coated α-
BDNF 
antibody (type 
not declared) 
Pre-coated α-
BDNF 
antibody 
(mouse 
monoclonal) 
Pre-coated α-
BDNF 
antibody 
(mouse 
monoclonal) 
Mix of: 
magnetic 
beads coated 
with α-BDNF 
Ab OR α-
Prolactin 
(types not 
declared) 
Manually 
coating with α-
BDNF Ab 
(mouse 
monoclonal) 
1000X, 20ul 
Pre-coated α-
BDNF 
antibody 
(mouse 
monoclonal) 
Primary 
detection 
antibody 
Biotinilated α-
BDNF 
antibody (type 
not declared); 
105 ul/vial, 
10X, 1 vial 
Biotinilated α-
BDNF 
antibody 
(maybe 
mouse 
monoclonal); 
110 ul/vial, 
100X, 2 vial 
Biotinilated α-
BDNF 
antibody 
(mouse 
monoclonal); 
25 ul/vial, 
1000X, 1 vial 
Mix of: 
Biotinilated α-
BDNF 
antibody AND 
α-Prolactin 
(type not 
declared); 
3200 ul/vial, 
1X, 1 vial 
α-BDNF Ab 
(chicken 
polyclonal) 
500X, 20ug 
α-BDNF 
antibody 
(mouse 
monoclonal)-
HRP 
conjugated 
11000 ul/vial, 
1X, 1 vial 
Type of 
secondary 
detection 
Streptavidin-
HRP 
conjugate, 
60ul/vial, 
200X, 1 vial 
Streptavidin-
HRP 
conjugate, 
110ul/vial, 
100X, 2 vial 
Streptavidin-
HRP 
conjugate, 
50ul/vial, 
1000X, 1 vial 
Streptavidin-
Phycoerythrin 
conjugate, 
5500ul/vial, 
1X, 1 vial 
Anitibody 
α-IgY-HRP 
conjugated, 
100ul/vial, 
200X, 1 vial 
/ 
Sample 
dilution 
(used) 
1:40 1:200 1:200 1:10 1:200 1:20 
Declared 
species 
cross-
reactivity 
Only human Human, 
mouse, rat 
and others 
Human and 
rat 
Only human Not declared Only human 
Processing 
time 
6-7 hours 3-4 hours Overnight 
incubation (16 
hours) 
+ 5-6 hours 
=21-22 hours 
Overnight 
incubation 
(16 hours) 
+ 3-4 hours 
=19-20 hours 
Overnight 
incubation (16 
hours) 
+ 7-8 hours 
=23-25 hours 
4-5 hours 
 
Table 4 BDNF ELISA Kits. Description and main characteristics of the tested BDNF ELISA kits 
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Figure 4.1 BDNF serum levels measured with the indicated ELISA assays.  Box plot of serum BDNF 
concentrations (ng/ml) from healthy volunteers (n=38-40, see Table 5) represented as mean of two 
independent measures. The upper line of the box marks the 75th percentile, the middle line is the median 
value and the lower line specifies the 25th percentile. Whiskers above and below the box indicate the 90th 
and 10th percentiles, respectively. Dots indicate the outlier values within each group. (#P<0.05 using 
ANOVA on ranks test with respect all tested kits).  
 
Intrinsic assay quality was evaluated by testing the intra-assay and the inter-assay 
coefficients of variation (CV) for each kit brand (Table 4). Intra-assay CV was assessed by 
comparing BDNF concentration values measured twice into the same plate, for each 
subject. Five kits presented values within the declared CV, with the only exception of 
Millipore-Milliplex® which showed a higher than expected intra-assay CV (13-14% versus 
<10%). 
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Number of 
plates tested: 2 
Aviscera-
Bioscience 
(n=38) 
Biosensis 
(n=39) 
Millipore 
ChemikineTM 
(n=39) 
Millipore 
Milliplex® 
(n=38) 
Promega 
Emax® 
(n=40) 
R&D 
System  
Quantikine® 
(n=40) 
Range ng/ml: 
min-max 14.1 - 32.4 13.6 - 41.4 1.7 – 29.1 8.7 - 32.4 12.1 – 27.5 15.4 – 46.2 
Median ng/ml  
(25% - 75%)  
20.7    
(18.5-24.4) 
25.4     
(21.5-32.0) 
9.8      
(8.1-17.2) 
18.2     
(14.2-22.2) 
19.0   
(16.9-21.7) 
25.5    
(21.0-30.5) 
Declared intra-
assay CV 4 – 6 % 2 – 6 % 4 % < 10 % 2 – 9 % 4 – 6 % 
Tested intra-
assay CV  
 
2 % - 3 % 1 % - 1 % 2 % - 3% 14 % - 13 % 3 % - 7 % 6 % - 5 % 
Declared inter-
assay CV 8 - 10 % 5 - 8 %  9 % < 10 % < 9 % 8 – 11 % 
 Tested inter-
assay CV 12 % 5 % 38 % 18 % 16 % 20 % 
 
Table 5 BDNF ELISA kits performance. Comparison between declared performances and actual tested 
performances of the specified BDNF ELISA kits. Median and range values, intra- and inter-assay 
coefficients of variation (CV) were assessed by measuring BDNF serum level from healthy volunteers 
(n=38-40). All the kits, except Milliplex®, which is based on multiplex technology (Luminex®/xMAP®), are 
based on classical sandwich ELISA.  
 
Measurements of BDNF concentrations were repeated on a different day by the same 
experimenter using two different plates of the same kit and then, inter-assay reproducibility 
was verified by one-way ANOVA for repeated measures (Figure 4.2). With the only 
exception of Biosensis, which showed reproducible results, five kits provided significantly 
different results between plate at Day 1 and plate at Day 2 (Figure 4.2). As a 
consequence, the inter-assay CV tested showed values higher than the declared one, with 
the exception of Biosensis (5% tested, versus 5-8% declared). The worst performance was 
obtained by the Millipore-ChemikineTM kit, with a 38% of inter-assay CV, which is far from 
the 9% stated by the manufacturer. 
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Figure 4.2 Inter-assay variation of the BDNF ELISA kits. Scatter plot showing the BDNF values 
distribution measured by the same operator on two different days using two plates of the same lot for each 
brand (Day 1 & Day 2). Each dot represents a BDNF value from one subject and the dashed lines link 
together two assessments of the same subject. The reproducibility was checked performing one-way 
ANOVA for repeated measures and the P values are specified. All tested kits except Biosensis showed a 
significant difference between the repeated measures of the same sera. 
 
To complete the assessment on the assay performance, we verified if the detection 
antibodies of each kit were able to recognize mature BDNF or proBDNF, or both, in a dot 
blot assay (Figure 4.3). In the case of the Promega kit, also the capture monoclonal 
antibody was available (mAb). As a negative control, we spotted on the same membrane 
strip Bovine Serum Albumin (BSA) and, as a positive control, the BDNF standard provided 
in each kit (standard-BDNF; Figure 4.3 A). In addition, a monoclonal anti-BDNF antibody 
commercially available from Sigma was tested on mature BDNF or proBDNF. Results 
demonstrated similar reactivity of the antibodies against commercial mature BDNF from 
Alomone Labs or Sigma (1000 pg). Biosensis, Millipore (both kits) and Promega antibodies 
reacted also with pro-BDNF while those from Aviscera-Bioscience and R&D System-
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Quantikine® showed only marginal reactivity to pro-BDNF (Fig. 4.3 A). Of note, Aviscera-
Bioscience and R&D System-Quantikine® kits claimed to be specific for mature BDNF and 
to cross-react by a 13 % with the human pro-BDNF. Since some antibodies resulted to 
have a very strong reactivity against pro-BDNF, the spotted quantity of pro-BDNF was 
reduced (1:100) respect to mature BDNF. To better evaluate reactivity against pro-BDNF, 
the central region of the dot-blot shown in Figure 4.3 A was overexposed (Figure 4.3 B; 10 
pg of pro-BDNF). Moreover, Figure 4.3 C shows the reactivity of Promega (pAB), 
Biosensis and Sigma against the same amount of pro-BDNF and mature-BDNF (100 pg) 
spotted on the substrate, highlighting a stronger reactivity of these antibodies against pro-
BDNF with respect to mature-BDNF. 
 
Figure 4.3 Line-blot for qualitative analysis of anti-BDNF antibodies specificity. A) The antibodies from 
each ELISA kit were tested for specificity against pro-BDNF or mature-BDNF. The BDNF standards blotted 
were commercial pro-BDNF (Alomone; 10 pg/lane), mature-BDNF (1 and 2 from Alomone and Sigma, 
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respectively; both 1000 pg/lane) and the standard-BDNF protein included in each kit (Aviscera and 
Biosensis: 10 pg/lane; Millipore-ChemikineTM, Millipore-Milliplex®- and R&D System-Quantikine®: 100 
pg/lane; Promega-Emax®: 1000 pg/lane). BSA (1000 pg/lane) was used as a negative control. The mouse 
monoclonal anti-BDNF antibody, (1:1000; Sigma) was tested as a control. B) Central region of the same blot 
shown in A, from an overexposed film to better visualize the reactivity against pro-BDNF. C) Reactivity of 
antibodies from Biosensis, Promega pAb and Sigma on a dot blot in which the same quantity of pro-BNDF 
and mature BDNF were spotted (100 pg each). Each antibody from the ELISA kits was used at the dilution 
suggested by the manufacturer’s instructions. mAb: Promega monoclonal capture antibody for plate coating. 
pAb: Promega polyclonal detection antibody. 
 
 
 
Figure 4.4 Graphic summary of BDNF ELISA kit performances. Polar plot showing the kit 
performances based on intra-precision (1 - intra assay coefficient of variation), inter-precision (1 -inter assay 
coefficient of variation), range, sensitivity and processing time. The black solid line indicates the assessed 
performances, while the dashed line shows those declared by the manufacturers. To obtain a graphical 
comparison, the best value for each factor among the six kits was set as the reference (100%; bold grey line); 
the highest the value, the better was the score. For sensitivity, the best value was defined after correction for 
the dilution factor. Concerning the processing time, values were normalized against an ideal value set as t=0 
hour (100%) over 24 hour (0%); the higher the value, the faster the processing. The declared processing 
times were essentially equal to the effective times. 
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The performance of the six BDNF kits examined is summarized graphically in Figure 4.4. 
The largest area corresponds to the most performant assay, taking as 100% the best 
performance measured among the six kits for five parameters: intra-assay variation, inter-
assay variation, detection range, sensitivity and processing time (see figure legend for 
definitions).  
We found that five out of six kits (Aviscera-Bioscience, Millipore-ChemikineTM and 
Milliplex®, R&D System-Quantikine® and Promega-Emax®) exhibited a high inter-assay 
variation, because two measurements of the same serum sample performed in two distinct 
days were significantly different. 
 
 
4.2 AIM 2- BDNF and immune mediators in job-related chronic stress 
 
4.2.1 Demographic variables 
We undertook a study aimed at address a possible relationship between the serum levels 
of BDNF, other trophic factors, cytokines and chemokines with the scores of job-related 
psychophysical stress and burnout. As described in materials and methods, 122 subjects 
among Italian healthcare assistants match the inclusion criteria for this study; demographic 
values as age and body mass index (BMI), separated by gender, are given in table 6.  
 
  N Mean SD Min/Max P 
Age, 
years 
Female 87 44.92 8.29 25/60 0.434 Male 35 46.23 10.98 25/67 
BMI, 
kg/m2 
Female 86 23.03 2.75 17.72/33.46 
<0.001 Male 35 25.75 3.50 17.63/33.56 
 
Table 6. Age and BMI distributions split by gender. Population sizes (N), average values (mean), standard 
deviations (SD) and minimum and maximum values (min/max) are given, along with p values (P) marked in 
bold. 
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Of note, BMI scores in female were significantly lower than those in male population 
(Mann-Whitney U test, z=-4.508, p<0.001). 
Psychophysical stress was assessed using five items, namely anxiety, emotion 
(depression-like), gastrointestinal disturbances, cardiac disturbances, ergonomic 
dysfunction at the workplace and by an overall “stress” item, defined as the average of the 
five items. The burnout state was assessed using the three items of emotional exhaustion, 
depersonalization, and personal accomplishment. The score distributions of both 
psychophysical stress and burnout state are given in table 7 (A and B respectively). 
Differences in the number of valid cases are because many subject missed to answer few 
item questions, so were treated as invalid.  
A 
Statistics 
 Anxiety Emotion Gastric Cardiac Ergonomics Stress 
N Valid 115 115 115 115 115 115 
Missing 7 7 7 7 7 7 
Mean 2.41 1.77 2.07 1.58 2.59 2.08 
Std. Deviation 1.04 0.80 1.01 0.85 1.13 0.81 
Minimum 1.00 1.00 1.00 1.00 1.00 1.00 
Maximum 5.40 5.00 6.00 5.00 5.40 5.16 
 
B 
Statistics 
 Emotional Exhaustion Depersonalization Personal Accomplishment 
N Valid 118 121 122 
Missing 4 1 0 
Mean 22.77 9.66 34.52 
Std. Deviation 7.30 3.60 4.94 
Minimum 9.00 5.00 24.00 
Maximum 41.00 22.00 47.00 
 
Table 7. A) Scores distribution of psychophysical stress items B) Scores distribution of burnout state items 
 
 
The first step was to verify if the demographic variables account for distribution differences 
among the different items. Indeed, performing a non-parametric Kruskal-Wallis test, we 
found that female subjects had significantly higher score values than male for all the 
psychophysical stress items, as shown in table 8. Concerning the burnout state, female 
display higher score values only for emotional exhaustion but not for depersonalization, 
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which is higher in male; no differences between male and female in the scores of personal 
accomplishment.  
 
Psychophysical  Female. N=82; 
 Mean rank 
Male. N=33; 
Mean rank Chi-Square df Asymp. Sig. P 
Anxiety 62.86 45.92 6.11 1 0.013 
Emotion 63.40 44.59 7.56 1 0.006 
Gastric 62.53 46.74 5.34 1 0.021 
Cardiac 62.15 47.68 5.01 1 0.025 
Ergonomics 62.51 46.80 5.24 1 0.022 
Stress 63.68 43.88 8.30 1 0.004 
      
Burnout  Female N; Mean rank 
Male 
N; Mean rank Chi-Square df Asymp. Sig. P 
Emotional Exhaustion 83; 64.47 35; 47.71 5.92 1 0.015 
Depersonalization 87; 56.81 34; 71.72 4.46 1 0.035 
Personal Accomplishment 87; 59.25 35; 67.09 1.23 1 0.267 
 
Table 8. Results of comparison (Kruskal-Wallis test) between female and male scores of psychophysical and 
burnout items. Sizes, (N), rank values, chi-square, degrees of freedom (df) and asymptotic p values (Asymp. 
Sig. P) are given. In bold are highlighted p<0.05. 
 
Regarding the confounding effect of BMI, after controlling for gender in a partial correlation 
analysis, we found that it negatively correlates with anxiety, gastrointestinal disturbance 
items and the overall stress state (see table 9 for correlation, df and p values). Differently, 
BMI did not correlate with any of the burnout item, even after gender control.  
Moreover, age did not correlate with any of the items, neither from psychophysical nor 
burnout states, even after controlling for gender or BMI (not shown). Of note, age showed 
a partial positive correlation with BMI, after controlling for gender (r=226, df=118, 
p=0.013). 
Due to given considerations, the variable “age” has not been considered any further, while 
corrections for gender and BMI have been performed in all subsequent analysis. 
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Partial Correlations 
Control Variable: Gender Anxiety Emotion  Gastric Cardiac Ergonomics Stress 
BMI (kg/m2) 
Correlation 
-0.230 -0.149 -0.295 -0.144 -0.054 -0.209 
Significance  
(2-tailed) 0.014 0.116 0.002 0.129 0.570 0.026 
df 111 111 111 111 111 111 
 
Table 9. Results of partial correlation analysis, controlling for gender, between BMI and the psychophysical 
stress items. Significant p values (p<0.05) are highlighted in bold; df, degrees of freedom. 
 
 
4.2.2 Biochemical variables 
The pre-analytical stages, consisting in serum samples collection and storage, were 
performed as described in the previous section (AIM 1). For the analytical stage, taking 
advantage of the multiplex technology, we screened 48 analytes among cytokines, 
chemokines and trophic factors; BDNF was assessed using the Biosensis kit, which 
exploits a sandwich ELISA technology and which resulted to be the most reliable among 
six kits tested (see AIM1, Table 1, Materials and Methods). The following analytes (11) 
were excluded from the dataset because more than 30% of samples were below the lower 
limit of detection (Out-Of-Range or OOR values): IL-2, IL-15, IL-1α, IL-3, IL-12p40, IFN-α2, 
LIF, MCP-3/CCL7, M-CSF/CSF1, β-NGF, TNF-β. The distribution values of the remaining 
analytes (38) are listed in table 10. 
Statistics 
Variable ID (pg/ml) 
N 
Median Minimum Maximum 
Percentiles 
Valid Missing 25 % 75 % 
IL-2Rα 122 0 43.44 0.07 163.78 21.38 61.80 
IL-16 122 0 61.91 0.13 842.08 37.53 93.70 
IL-18  122 0 38.74 3.12 184.56 24.06 53.88 
CTACK/CCL27 122 0 510.01 124.57 1335.66 389.95 654.04 
GRO-α/CXCL1 122 0 52.62 0.24 253.39 28.56 84.34 
HGF  122 0 424.84 66.67 1707.16 276.12 595.51 
MIF  122 0 308.09 18.51 7937.97 198.25 438.75 
MIG/CXCL9 122 0 426.46 68.47 3821.65 272.02 577.60 
SCF  122 0 61.21 0.25 261.82 37.41 95.12 
SCGF-β/CLC11  122 0 19584.75 398.76 68535.28 12747.37 28157.71 
SDF-1α/CXCL12  122 0 99.24 0.29 438.52 46.54 164.28 
TRAIL/TNFSF10 122 0 43.07 0.46 557.24 0.46 69.81 
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Table 10. Distribution values in pg/ml of circulating cytokines, chemokines and growth factors.  
 
Because 30 persons out of 122 use pharmaceutical drugs, we verified if drug assumption 
has an impact on the analytes levels. As a result, many of the analytes (21) showed 
significant different levels between cases who use drugs and who do not (Kruskal-Wallis 
test; see table 11). In general, drugs had a negative influence on analytes level, with the 
exception of INF-γ, MIP-1β and RANTES, of which we observed increased median values 
in drug users. 
 
Variable ID NO Drugs N; Mean rank 
Drugs 
N; Mean rank Chi-Square df Asymp. Sig. P 
IL-2Rα 92; 70.41 30; 34.17 23.86 1 <0.001 
IL-16 92; 67.92 30; 41.82 12.37 1 <0.001 
IL-18  92; 69.52 30; 36.90 19.25 1 <0.001 
CTACK/CCL27 92; 66.08 30; 47.47 6.27 1 0.012 
GRO-α/CXCL1 92; 67.49 30; 43.13 10.79 1 0.001 
HGF  92; 66.46 30; 46.28 7.37 1 0.007 
MIF  92; 68.57 30; 39.82 14.96 1 0.000 
MIG/CXCL9 92; 65.16 30; 50.27 4.01 1 0.045 
SCF  92; 66.20 30; 47.10 6.61 1 0.010 
SDF-1α/CXCL12  92; 65.88 30; 48.08 5.77 1 0.016 
TRAIL/TNFSF10 92; 71.45 30; 30.98 30.55 1 <0.001 
IL-5 91; 69.46 30; 35.33 21.81 1 <0.001 
IL-7 91; 68.25 30; 39.00 15.70 1 <0.001 
IL-1β 121 1 1.56 0.24 7.57 0.97 1.89 
IL-1Rα 121 1 104.04 11.71 2462.88 68.79 150.97 
IL-4  121 1 2.79 0.95 5.51 2.19 3.32 
IL-5  121 1 1.47 0.02 11.37 0.29 2.37 
IL-6  121 1 5.15 0.86 280.59 3.62 7.57 
IL-7  121 1 6.81 1.68 33.64 4.75 9.75 
IL-8/CXCL8 121 1 15.24 3.26 34.12 12.32 20.04 
IL-9  121 1 11.57 3.00 785.62 8.36 19.83 
IL-10  121 1 4.25 0.01 277.64 2.26 7.68 
IL-12 (p70)  121 1 30.37 0.03 787.62 16.76 50.00 
IL-13  121 1 4.92 0.30 40.25 3.19 7.05 
IL-17 121 1 47.95 0.22 307.36 17.27 88.08 
Eotaxin/CCL11 121 1 139.26 8.71 2109.58 88.17 202.52 
FGF basic  121 1 63.88 22.46 277.42 48.61 83.74 
G-CSF  121 1 29.28 9.92 140.54 21.86 42.40 
GM-CSF  121 1 11.60 0.15 172.01 2.42 20.70 
IFN-ᵞ 121 1 147.34 25.32 621.07 96.56 182.18 
IP-10/CXCL10 121 1 917.03 302.60 3190.41 662.03 1216.50 
MCP-1/CCL2 (MCAF)  121 1 23.85 3.18 82.55 16.41 33.39 
MIP-1α/CCL3  121 1 3.89 1.43 15.00 2.94 5.40 
PDGF-BB  121 1 4579.39 1504.00 12052.56 3597.62 6303.76 
MIP-1β/CCL4 121 1 85.06 23.18 661.33 62.62 103.67 
RANTES/CCL5 121 1 16944.41 3746.43 71382.91 12216.15 21775.42 
TNF-α  121 1 23.90 7.75 4710.80 19.41 30.13 
VEGF  121 1 66.53 13.83 610.35 39.40 112.03 
BDNF (ng/ml) 120 2 28.61 11.66 54.02 22.19 34.82 
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IL-10 91; 67.16 30; 42.32 11.32 1 0.001 
IL-13 91; 65.90 30; 46.13 7.17 1 0.007 
IL-17 91; 65.36 30; 47.77 5.68 1 0.017 
FGF basic 91; 66.40 30; 44.63 8.69 1 0.003 
IFN-γ 91; 55.08 30; 78.97 10.47 1 0.001 
MIP-1α/CCL3 91; 66.45 30; 44.47 8.86 1 0.003 
MIP-1β/CCL4 91; 55.95 30; 76.33 7.62 1 0.006 
RANTES/CCL5 91; 56.11 30; 75.83 7.13 1 0.008 
 
Table 11. Comparison (Kruskal-Wallis test) between distribution levels of analytes in subjects how use 
drugs and how do not. Sizes, (N), rank values, chi-square, degrees of freedom (df) and asymptotic p values 
(Asymp. Sig. P) are given. Here are listed only the significantly different (p<0.05) comparisons. 
 
There was no difference in gender distribution among drug users (Female/Male, 20/10, 
p=0.068); moreover there was also no significant difference between the scores of both 
psychophysical stressors and burnout items in subjects who use drugs and who do not 
(Kruskal-Wallis test; not shown). Given that and to the high influence of drugs on biological 
variables, in order to limit this confounder and increase the power of predictors, we 
decided to exclude all the 30 subjects who use drugs. Distribution of psychophysical and 
burnout scores of the remaining 92 cases were essentially equal to the previous ones (not 
shown). 
After that, since most of the biological variables were not normally distributed, we log 
transformed all independent variables (including BMI), attempting to achieve normal 
distribution: Shapiro-Wilks test for normality not always gave non-significant results (not 
shown), but Q-Q plot analysis displays a good approximation to normal distribution (see 
example in Figure 4.5). 
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Figure 4.5 Representative Q-Q plot from MCP-1/CCL2 before (left) and after (right) log transformation 
 
The presence of inferred values for those under the lower limit of detection (OOR), 
introduced a strong bias in the distribution of the following variables, even after log 
transformation: IL-1β (26%), IL-5 (26%), GM-CSF (24%), IL-2Rα (4%), IL-16 (5%), GRO-
α/CXCL1 (6%), SCF (4%), SDF-1α/CXCL12 (7%), TRAIL/ TNFSF10 (14%). An example of 
this effect is displayed by the frequency distribution graph of IL-1β in figure 4.6.  
 
Figure 4.6 Distortion on frequency distribution 
introduced by inferred OOR values (red box), 
despite the usage of log transformed values. Black 
curve indicates the shape of theoretical Gaussian 
distribution. Here is reported IL-1β as an example, 
but the effect of the presence of inferred OOR value 
is similar for other analytes (see text). 
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Since these OOR cases were randomly distributed among psychophysical stress or 
burnout scores, we applied a stringent criterion and decided to exclude these variables 
from further analysis.  
 
4.2.3 Univariate analyses 
The transformation of the predictor variables, in order to approximate normal distributions, 
allow to more reliably correlate independent variables (analytes) and dependent variables 
(item scores), which are both continuous scale, and permit also to perform subsequent 
multivariate analysis. As univariate analysis, we performed partial correlations using the 
log-transformed data, controlling for gender and BMI, in order to detect association 
between each predictors (29 in total) and the psychophysical stressor or burnout items. 
Significant associations were found for only 8 independent variables, i.e. CTACK, IL-6, IL-
17, Eotaxin, MCP1, Rantes, BDNF and MIF. The table 12 summarizes the significant 
results:  
69 
 
Variable ID Anxiety Gastric Cardiac Ergonomics Stress Depersonalization 
Eotaxin/CCL11 
(df=83) -0.304 (0.005) -0.325 (0.002)  -0.240 (0.027) -0.307 (0.004)  
CTACK/CCL27 
(df=84) -0.301 (0.005) -0.235 (0.029) -0.272 (0.011)  -0.258 (0.017)  
MCP-1/CCL2 
(df=83) -0.342 (0.001) -0.214 (0.049)   -0.263 (0.015)  
RANTES/CCL
5 (df=83) -0.320 (0.003)   -0.221 (0.042) -0.274 (0.011)  
BDNF 
(df=82)    0.284 (0.009)   
IL-17 
(df=83)  0.280 (0.010)     
IL-6 
(df=83) -0.223 (0.040)      
MIF 
(df=87)      0.210 (0.049) 
 
Table 12. Summary of the significant results from partial correlation analysis, controlling for gender and 
BMI, between biological variables (independent variables, first column) and scores of the psychophysical 
stress and burnout items (first row). Correlation values (minus sign indicate a negative correlation) and p 
values in brackets, highlighted in bold, are given. 
 
For psychophysical stressor items, the majority of the associations are negative, except for 
IL-17 with the Gastric disturbance and for BDNF with the Ergonomics problems. No 
associations with any of the predictors were found for the Emotion item. For burnout state, 
only an association between a slight increase in MIF levels and Depersonalization was 
found. Results are also graphically summarized as scatter plots in Figure 4.7  
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 Figure 4.7 Scatter plots showing correlations between the given chemokines (MCP-1/CCL2, 
Eotaxin/CCL11, CTACK/CCL27, RANTES/CCL5), cytokines (IL-6, IL-17, MIF) and trophic factor 
(BDNF) and the items of psychophysical stress in panel A and burnout in panel B. Regression lines, R 
square and p values are displayed. 
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4.2.4 Multivariate analyses 
Multivariate analysis was also performed to explore association between predictors, and 
partial least square regression procedure (PLS) is well suited for this purpose; in fact is 
particularly useful when predictor variables are highly correlated or the number of 
predictors is considerable in respect to the number of cases. It extracts, at first, several 
latent factors that explain as much of the covariance as possible between dependent and 
independent variables and then computes a series of score (Variable Importance to the 
Projection or VIP) that help to identify predictors that best contribute to the association with 
the dependent variable. As done before with partial correlation analysis, for PLS we used 
each item of the psychophysical stress state as dependent variable and cytokines, 
chemokines, growth factors and the interaction effect between gender and BMI as 
independent variables. The graphs in Figure 4.8 show the contribution of information (VIP) 
of each variable to the item of anxiety, gastric and cardiac disturbances, ergonomic 
problems and overall stress. Results essentially replicated the findings obtained with the 
partial correlation analysis, in which the chemokines MCP-1/CCL2, RANTES/CCL5, 
CTACK/CCL27, Eotaxin/CCL11, the interleukin 17 and the BDNF are the best 
contributors. Other analytes, which were not identified in partial correlation analysis, shows 
up with PLS: IL-9 for anxiety and cardiac problems, IL-18 for ergonomic problems and 
overall stress and MIP-1β/CCL4 for gastric problem and overall stress. Differently, IL-6 
was weakly associated with anxiety score as well with any other stress item. 
Results for burnout are not displayed since PLS analysis did not replicate the already 
weak association between depersonalization and MIF. Likewise, no other association 
showed up, since VIP scores were close to one for all biological variables (not shown). 
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Figure 4.8 Variable Importance 
to the Projection (VIP) ranking 
biological markers for their 
contribution to the association to 
psychophysical stress items, 
assessed by PLS discriminant 
analysis. 
73 
 
In addition to PLS, we performed factor analysis (FA) for unsupervised analysis of the 
dataset, aimed at identifies underlying variables (latent factors) that explain the correlation 
within the set of observed variables. Unlike PLS, FA does not extract predictors based on 
the item scores (dependent variable), that is the reason of the term “unsupervised 
analysis”, but does not permit the use of categorical variables (i.e. gender). Performing the 
Principal Axis Factor method (PAF), which is similar to the Principal Component Analysis 
(PCA) and gives similar results, we identified the presence of 7 different latent factors, 
which explained 74% of the total variance (see table 13 A). Interestingly, the independent 
variables, identified by PLS and partial correlations as potential indicators of the several 
psychophysical stress items, were found to belong to different latent factors (see table 13 
B), highlighting bona fide their independence (despite used Promax rotation algorithm 
allowed for some grade of correlation between factors; however, the Varimax rotation 
algorithm does not permit correlation between factors but gave similar results). There are 
two exceptions to the above statement: 1) Eotaxin/CCL11 and MCP-1/CCL2 were in the 
same latent factor and the correlation analysis confirmed that these two variables were 
significantly associated (r=0.582; df=83; p<0.001). 2) BDNF and BMI were in the same 
latent factor and they showed a positive correlation (r=0.303; df=83; p=0.005)  
A 
Factor 
Total Variance Explained 
Initial Eigen values 
Total % of Variance Cumulative % 
1 10.929 36.428 36.428 
2 3.073 10.243 46.671 
3 2.433 8.108 54.779 
4 1.838 6.125 60.905 
5 1.513 5.043 65.948 
6 1.333 4.442 70.390 
7 1.137 3.792 74.182 
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B 
Pattern Matrix 
Variable ID 
(log 10 transformed data) 
Factor 
1 2 3 4 5 6 7 
IL-4 0.991       
IL-8 0.973       
G-CSF 0.892       
IFN-γ 0.866       
RANTES/CCL5 0.683    0.421   
PDGF-BB 0.458       
MIP-1β/CCL4        
TNF-α        
IL-10  0.997      
IL-12  0.865      
IL-13  0.596      
IL-7  0.515      
VEGF  0.498      
MCP-1/CCL2 (MCAF)   0.867     
IL-1Rα   0.728     
Eotaxin/CCL11   0.637     
IL-6   0.494     
SCGF-β/CLC11        
FGF basic    0.835    
IL-17    0.829    
MIP-1α/CCL3    0.707    
IL-9    0.580    
IL-18     0.698   
CTACK/CCL27     0.688   
HGF     0.624   
MIF     0.506   
MIG/CXCL9      0.792  
IP-10/CXCL10      0.692  
BDNF       0.598 
BMI       0.575 
 
Table 13. Results from the unsupervised analysis performed using Principal Axis Factoring as extraction 
method. A) Number of factor extracted based on Eigen values >1; the percentage of variance explained by 
each factor and the total cumulative percentage are displayed. B) Matrix table showing the correlation values 
connecting variables (first column) to each latent factor (head row) obtained using Promax rotation method 
with Kaiser normalization. The variables of interest are underlined. Values less than 0.4 are hidden. 
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Taken together, the presented results pointed out a connection between some elements of 
the chemokine pattern and the features of the chronic psychophysical stress. Interestingly, 
peripheral BDNF was positively associates with the score of the ergonomic problems at 
the workplace. 
 
4.3 AIM 3- BDNF expression in cells under cytotoxic stress 
 
To further explore the potential protective role of BDNF in chronic stress conditions, we 
moved to an in-vitro cellular model of cytotoxic stress, consisting in SK-N-BE human 
neuroblastoma cell line treated with the cisplatin drug. Cisplatin is a non-cell cycle specific 
alkylating agent forming intrastrand DNA crosslinks and adducts that cause changes in the 
conformation of the DNA leading to a blockade of DNA replication and activation of signal 
transduction pathways, including those involving ATR, p53, p73, and MAPK, which 
culminate in the activation of apoptosis. Other mechanisms of cisplatin cytotoxicity include 
mitochondrial damage, decreased ATPase activity, and altered cellular transport 
mechanisms (Siddik, 2003). The choice for this type of model has been driven by different 
reasons: 1) SK-N-BE is a neural crest, tumour-derived human cell line that is well 
characterized, easy to culture and express both BDNF protein and TrkB receptor after 
differentiation induction. 2) Chemotherapeutic drugs, such as cisplatin, are known to give 
stressful insult to tumour cells, so the effect of prolonged treatment (death or resistance) 
can be conveniently compared to the effect of chronic stressors at cellular level. 3) Any 
finding that gives some clues inside the mechanisms of drug-induced cell death or 
resistance may have a potential clinical impact, since neuroblastoma tumours are 
responsible for at least 15% of cancer-related deaths in children; moreover, in this tumour, 
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expression of BDNF and its associated receptor (TrkB) are associated to a more malignant 
phenotype. 
  
4.3.1 Cisplatin treatment increases BDNF in differentiated SK-N-BE neuroblastoma 
cells 
We previously demonstrate that SK-N-BE neuroblastoma cells differentiated with 9-cis 
retinoic acid show higher production of BDNF and its receptor, TrkB. Moreover, they are 
more resistant to cisplatin induce death, with respect undifferentiated cells, while BDNF 
silencing attenuate this effect (Baj and Tongiorgi, 2009). Giving these observations, we 
investigated whether cisplatin is able to modulate BDNF expression. SK-N-BE cells were 
then differentiated for 4.5 days with 9-cis retinoic acid followed by cisplatin treatment (5 
µg/ml) in serum-free medium for one, three, six, twelve and twenty-four hours. After RNA 
extraction and retro-transcription, total BDNF transcripts were quantified through real time 
PCR (N=3 independent cultures) and we found a significant increment (3 folds, P<0.001) 
in BDNF coding sequence mRNA already after six hours, which is stable up to twelve 
hours and more pronounced (9 folds, P<0.001) after 24 hours of treatment (Figure 4.9 B). 
BDNF has a complex gene structure (see Figure 4.9 A) characterized by different 5’-
untranslated (UTR) exons spliced to a common coding sequence (CDS) linked to a 3’UTR 
that exists in two forms, one short and one long, due to the presence of two 
polyadenylation sites. The different BDNF splice variants are transcribed independently 
and give rise to a total of 22 possible transcripts in rodents, 34 in humans (Aid et al., 2007; 
Pruunsild et al., 2007; Pruunsild et al., 2011). 
As a consequence, the increased expression was not limited to the coding sequence but 
involve almost all transcript variants (1, 2, 3, 4, 6, 7 and 9a), especially after 24 hours. The 
exceptions regarded the expression of exons 5 and 8 which was slightly increased, 
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although not significantly. Additionally, expression of exons 3, 6 and 7 was increased 
already after 6 hour of cisplatin treatment while, on the contrary, we observed a transient 
reduction in the expression of exon 4 at this time point (Figure 4.9 C).  
 
Figure 4.9 A) BDNF human gene structure accordingly to Pruunsild et al. (2007) B) Total BDNF CDS 
expression in SK-N-BE cells (differentiated 4.5 DIV) and treated in serum free medium (SFM) + Cisplatin (5 
µg/ml ). RNA extracted at different time points (hour after treatment) (N=3). C) Single BDNF mRNA 
isoforms modulation at the chosen treatment time points (T0 = control; T6 = 6 hours; T24 = 24 hours) (N ≥ 
4). B and C data were collected through real time PCR with SYBR® Green Technology (*P<0.05, **P<0.01; 
***P<0.001, one-way ANOVA). 
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In parallel to the increased mRNA expression, also BDNF protein production was 
enhanced by cisplatin treatment. Using the ELISA technique, we found that after a slight 
but significant decrease at 1 hour of treatment, there was a recovery of BDNF to control by 
12h while the chronic treatment with cisplatin for 24 hours boosted the BDNF protein levels 
of almost 20 % over the basal level (untreated control; P<0.001, one-way ANOVA; see 
figure 4.10 A). Similar results were obtained also by western blot analysis. Indeed, there 
was no significant variation in BDNF level after 6 hour but after 24 hour of treatment there 
was an almost 30% increase in BDNF protein production (P<0.001, one-way ANOVA; 
Figure 4.10 B).  The observed reduction in the tubulin signal was an expected finding 
which reflects a reduction in cell number due to increased cell death in treated cultures.  
Since the different BDNF transcripts are upregulated by cisplatin treatment, we aimed also 
at determining which of them is more efficiently translated, hence contributing further to 
BDNF protein production. In a previous study from our laboratory, we developed an in vitro 
translation assay by which we demonstrated that the different BDNF transcripts display a 
different ability to translate, basally and after stimulation, and this ability is influenced by 
the presence of both 5’- and 3’-UTRs (Vaghi et al., 2014). Briefly, we transfected SK-N-BE 
cells with a construct that bear a Firefly luciferase (FLUC) reporter gene flanked by 
different 5’-UTR (exons 1, 2c, 4 and 6, alternatively) and the 3’-UTR long; exons 1, 2, 4 
and 6, all together, were the most abundant 5’UTR of BDNF transcripts. Simultaneously 
with each one of these vectors we co-transfected a control reporter, namely Renilla 
luciferase (RLUC), to normalize for differences in transfection efficiency. After treatments, 
FLUC bioluminescence activity was recorded and double normalized over the RLUC 
activity and the untreated condition. As a result from this translatability assay, we observed 
that after 24 hours of cisplatin treatment all tested transcripts underwent a significant 
increased translation (p<0.01 for exons 1, 2c, 4; see Figure 4.10 C); exon 6 translation 
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increment, although significant (P<0.05), displayed a high variability, possibly due to the 
fact that exon 6 is translationally repressed in basal conditions, so its contribution to BDNF 
protein production is limited, potentially reflecting a tight regulation. Of note, the 3’UTR 
long alone, does not substantially contribute to the translatability in stimulated conditions 
(Vaghi et al., 2014).  
  
 
Figure 4.10 A) ELISA detection of total 
BDNF protein level in 4.5 DIV 
differentiated SK-N-BE cells after cisplatin 
treatment, at different time points: 
untreated control (T0), 1 hour (T1), 3 (T3), 
6 (T6), 12 (T12) and 24 (T24) hours (N=4, 
each in duplicate).  
B) Evaluation of mature BDNF protein 
production through densitometric analysis 
of western blot, in the same conditions as 
described in panel A; BDNF signal is 
normalized to tubulin and given as 
percentage of variation with respect to 
control. Lower panel: representative 
western blot of mature BDNF and tubulin 
(N=3). 
C) Translatability capacity of different 
BDNF isoforms under cisplatin cytotoxic 
stress, at 6 and 24 hours time points. The 
isoforms tested are as follows: exon1-Fluc-
3’UTR long, exon2c-Fluc-3’UTR long, 
exon4-Fluc-3’UTR long and exon6-Fluc-
3’UTR long. Values from each isoform are 
normalized for transfection efficiency over 
a control vector (Rluc) and given as fold 
increase on basal condition (T0); N=3, each 
in duplicate; RLU: relative luciferase unit.  
In all panels, data are represented as mean 
± s.e.m. *P<0.05; **P<0.01; ***P<0.001, 
one-way ANOVA. 
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4.3.2 Aurora kinases inhibitor enhances the cisplatin cytotoxic effect 
To further explore the regulation mechanism of BDNF translation, we focused our attention 
on Aurora proteins, a family of serine/threonine kinases involved in translational regulation 
of diverse transcripts. The reasons for this choice are threefolds. First, Aurora kinases 
regulate translation by phosphorylation of cytoplasmic polyadenylation element binding 
protein (CPEB), which binds to cytoplasmic polyadenylation element (CPE) on mRNA 
transcripts and promotes translation induction (Groisman et al., 2006; Otto et al., 2009); 
this mechanism has been described also in dendritic spines, not only in tumuor cells 
(Huang et al., 2002). Second, all BDNF mRNA transcripts include a CPE element in the 3’-
UTR, before the first polyadenylation signal (Oe and Yoneda, 2010). Third, Aurora proteins 
are important regulators of the cell cycle, since deregulation of their activity can result in 
mitotic abnormality and genetic instability (Fu et al., 2007); moreover, both the expression 
level and the kinase activity of Aurora kinases are found to be up-regulated in many 
human cancers, including neuroblastomas, especially those with N-myc gene amplification 
(as SK-N-BE cells), which predicts poor prognosis and resistance to therapy (Otto et al., 
2009). Given that, inhibition of Aurora activity represents not only a tool to study 
translational regulation mechanisms, but also an important anticancer therapeutic target. 
Our hypothesis was that reducing Aurora kinase activity, by a potent inhibitor (PHA-
680632) (Soncini et al., 2006), we can enhance the cytotoxic stress effect of the cisplatin 
also as consequence of reduced BDNF translation. To demonstrate that, we treated SK-N-
BE cells with cisplatin and Aurora inhibitor PHA-680632 (10 µM), either alone or in 
combination, at the same time points described previously. At first, we test the cytotoxic 
effects through a MTT viability assay and found that combined treatment with cisplatin and 
Aurora inhibitor significantly reduced cell viability with respect untreated condition, after 24 
hours (DMSO; P<0.001, one-way ANOVA followed by Holm-Sidak correction). Cisplatin 
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and PHA-680632 together, at this time point, enhanced cell mortality of about 20% in 
comparison to cisplatin alone (not significant) and of more than 30% with respect Aurora 
inhibitor only (P=0.012, one-way ANOVA). Of note, these differences were maintained at 
all tested time points (Figure 4.11 A). Similar results were obtained also via 
immunofluorescence experiments in which we stained neuroblastoma cells nuclei with 
Hoechst and marked actin to point out cell bodies, in order to compare qualitative the 
effect of cisplatin only and cisplatin+PHA680632 treatments at 6 and 24 hours, with 
respect untreated condition. We also performed a quantitative assessment by counting 
cells in the different treatment conditions relative to the untreated control, which was set at 
100% (Figure 4.11, panels B and C). A reduction in cell number was obtained, in 
particular, after 24 hour of combined treatment with cisplatin and Aurora inhibitor 
(P=0.003; one-way ANOVA). 
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4.3.3 Effect of Aurora inhibition on BDNF protein production 
In the following series of experiments, we tested the effect of Aurora kinases inhibition on 
BDNF protein expression. We were expecting a decrease in BDNF protein levels reflecting 
a reduction in translatability of mRNA transcripts. Unexpectedly, we found exactly the 
opposite. In western blot experiments normalized to tubulin, after 24 hours of treatment 
BDNF signal was more than double with respect to untreated control (P<0.001, one-way 
ANOVA), while no significant change was observed after 6 hours (Figure 4.12 a). 
Performing a translation assay, we found that, while translation from exons 1, 2c and 4 
Figure 4.11 A) Residual viability in SK-N-BE 
cells treated for different hours with cisplatin 
and/or PHA-680632 (Aurora kinases 
inhibitor). All treatment were performed after 
4.5 DIV of differentiation and quantified 
through colorimetric MTT assay. DMSO 
treatment represent the control group. Data are 
given as mean ± s.e.m. of percentage viability 
(N=3, each in triplicate); ***P<0.001; 
**P=0.006. 
B) Immunofluorescence on SK-N-BE cells 
treated for 6 or 24 hours with cisplatin alone or 
in combination with PHA-680632 inhibitor. 
Hoechst was used to highlight nuclei and Actin 
was marked to emphasize cell bodies; the 
merge between the two channels is displayed. 
(N=3; scale bar: 20 µm). 
C) Cell count from the immunofluorescence 
described in panel B. Values are given as mean 
± s.e.m. of percentage of cell number with 
respect basal conditions (T0) (N=3; 
**P=0.003). 
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was unaffected at both 6 and 24 hours of combined treatment with cisplatin and Aurora 
inhibitor, translation from exon 6 was increased about 6 folds at 24 hours (but not 6) of 
treatment (P<0.001, one-way ANOVA; see Figure 4.12 B). This finding is consistent with 
the hypothesis of a tight regulation of the translation of transcripts bearing exon 6, 
consisting in a repressive state in basal conditions that is released under cytotoxic stimuli. 
Again, the 3’UTR long sequence alone did not affect translation under cisplatin treatment. 
The results of an increased production of BDNF protein were confirmed also by 
immunofluorescence. Using a monoclonal antibody, we were able to identify BDNF spots 
inside the neuroblastoma cells and we observed a clear enrichment of these spots after 24 
hours of treatment with cisplatin in the presence with the PHA-680632 Aurora inhibitor, in 
comparison to 6 hours or the untreated control (see upper row of panel C, Figure 4.12). 
Again, actin was marked in red to depict cell bodies; outline of the merged figures (see 
bottom row of panel C, Figure 4.12) are given, with black BDNF spots and red cell body 
edges, to highlight the rising number of spots and the fact that they are inside the cell 
boundaries. Panel D of Figure 4.12 simply displays the quantitative analysis of BDNF 
spots, which are given as number per micron square. From 0.21±0.04 BDNF spots/µm2 
(mean±S.E.M.) in basal condition, which was essentially stable after 6 hour of treatment 
either with cisplatin only or combined to PHA-680632, after 24 hours of treatment the 
number rised to 0.31±0.03 BDNF spots/µm2 with cisplatin alone (P=0.039, one-way 
ANOVA) up to 0.40±0.02 after treatment with both cisplatin and Aurora inhibitor (P=0.004, 
one-way ANOVA).  
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Figure 4.12 A) Evaluation of mature BDNF production, through western blot analysis and relative 
densitometric analyses, in differentiated SK-N-BE cells after cisplatin + PHA-680632 (Aurora K inhibitor) 
treatment, at different time points: untreated control (T0), 6 (T6) and 24 (T24) hours (N=3; ***P<0.001). 
B) Translatability capacity of different BDNF isoforms in differentiated SK-N-BE treated as described in 
panel A. The isoforms tested and the normalization procedures are the same as described in figure 2, panel C. 
RLU: relative luciferase unit (N=3, each in duplicate; ***P<0.001). C) Immunofluorescence on SK-N-BE 
cells treated with cisplatin ± PHA-680632 at the same time points described in panel A. BDNF spots are 
highlighted using a mouse mAb and actin is marked using a rabbit pAb to emphasize cell bodies; the merge 
of the two channel is given as well its outline, where black dot represents the BDNF spots and red lines the 
edges of the cell bodies. Images are analized after z-project from 11 stacks, performed using Fiji-ImageJ 
(N=3; scale bar: 10 µm). D) BDNF spot analysis from the immunofluorescence described in panel C. Data 
are given as mean ± s.e.m. number of spots per µm2 (N=3; **P=0.004, *P=0.039).  
 
85 
 
In conclusion, cisplatin induced cytotoxic stress was able to stimulate BDNF production by 
enhancing both transcription and translation of mRNAs. Additionally, the translation 
induction was particularly effective for transcripts bearing exon 6 along with the 3’UTR long 
sequence. Although the combined treatment with PHA-680632 Aurora kinases inhibitor 
resulted effective in enhancing the cytotoxic effect of cisplatin, we observed an 
enhancement in BDNF production in a subpopulation of cells that became resistant, thus 
suggesting induction of an Aurora kinase-independent mechanism for BDNF translation 
induction under cytotoxic stress conditions. 
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5. DISCUSSION 
5.1 AIM1 
Measuring BDNF, as well as other circulating markers, from body fluids in a reliable 
manner is often an underestimates issue that still undermine the reproducibility of results 
and make studies on similar topics difficult to compare. In the first part of the present work 
we propose a well reproducible BDNF quantification method potentially suitable also for 
clinical applications. To obtain a reduction in the variability of measurements due to 
technical issues, we defined a procedure to standardize the pre-analytical steps from 
blood collection to serum isolation and storage. Moreover, we identified the best 
performing assay for BDNF detection by comparing six widely used commercial kits based 
on the ELISA technique, the most common way to measure circulating BDNF and, 
according to our results, one of the main sources of inconsistencies among studies.  
A recurrent question among researchers is whether it is more correct to measure BDNF 
levels in plasma, serum or whole blood. We strongly advocate for the serum as elective 
body fluid for a reliable detection of circulating BDNF. There are several reasons that 
support this choice. First, BDNF concentration in serum is about 100 folds higher than 
plasma levels (Radka et al., 1996). Second, BDNF concentration in plasma is affected by 
handling of the blood sample because of the presence of platelets, which store BDNF and 
upon degranulation can secrete it (Fujimura et al., 2002; Karege et al., 2005). Simple 
shearing forces produced by the needle during blood withdrawal can cause platelet 
degranulation and even changes in room temperature and timing can produce significant 
release of BDNF in the plasmatic fraction (Elfving et al., 2010). In addition, it has been 
shown that because of the release from platelets, BDNF concentration raises 
progressively within few hours from plasma preparation (Elfving et al., 2010; Radka et al., 
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1996). Consequently, the BDNF quantification from plasma is extremely sensitive to 
preparation procedures and is very difficult to be reproducible among different operators. 
Secondly, release of BDNF from platelets can be influenced by age, specific disease 
conditions, or pharmacological treatments, which may be difficult to control (Karege et al., 
2005; Lommatzsch et al., 2005). Concerning the whole blood, although measurement of 
BDNF in serum and whole blood give comparable results, we agree with Elfing and 
colleagues (Elfving et al., 2010) that, since whole blood must be lysed before the BDNF 
measurements, the cell lysis step may add additional variability during sample preparation. 
In conclusion, since BDNF is not produced in megakaryocyte precursor cells but actively 
picked up by platelets from the circulating BDNF pool (Fujimura et al., 2002; Lommatzsch 
et al., 1999; Nakahashi et al., 2000), it can be assumed that serum seems reflect the 
totality of circulating BDNF. Indeed, serum BDNF concentration is almost identical to the 
amount of BDNF in washed plateled lysates (Fujimura et al., 2002; Lommatzsch et al., 
2004). In addition, while BDNF circulate in plasma for less than an hour, platelets circulate 
as much as 11 days (Kishino et al., 2001; Poduslo and Curran, 1996).  
The performance of the six BDNF kits examined is summarized graphically in Figure 4. 
The largest area corresponds to the most performant assay, taking as 100% the best 
performance measured among the six kits for five parameters: intra-assay variation, inter-
assay variation, detection range, sensitivity and processing time (see figure legend for 
definitions). We found that five out of six kits (Aviscera-Bioscience, Millipore-ChemikineTM 
and Milliplex®, R&D System-Quantikine® and Promega-Emax®) exhibited a high inter-
assay variation, because two measurements of the same serum sample performed in two 
distinct days were significantly different. Of note, Promega kit was previously 
demonstrated to give unreproducible results upon repeated measures on sera from 
Huntington’s disease patients (Zuccato et al., 2011). The only exception was the kit by 
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Biosensis, which showed the lowest (5%) coefficient of variation (CV) and no significant 
difference between two independent measurements. In terms of CV, Promega and 
Aviscera-Bioscience assays showed acceptable values (16% and 12% CV, respectively), 
although measured inter-assay variations were slightly higher than those declared by the 
manufacturers. Millipore-ChemikineTM showed the poorest performance in terms of inter-
assay variation (38%). Kit descriptions provided by producers indicated a factor 10 
difference in assay sensitivity between kits, ranging from 2 pg/ml to 20 pg/ml (mean 9.07 
pg/ml) and even greater differences in the range of detection, from the narrowest range of 
7.8-500 pg/ml for the Biosensis, Millipore-ChemikineTM and Promega kits, to the broadest 
range of 12-50,000 pg/ml provided by the Millipore-Milliplex® assay, which uses the 
Luminex®/xMAP® technology. All kits examined are able to detect BDNF within a restricted 
concentration range (from 7.8 pg/ml to 4 ng/ml), with the exception of multiplex assay 
which had a broader range (12 pg/ml to 50 ng/ml). Most studies including ours, report a 
range of BDNF concentrations between 8-46 ng/ml, with an average around 18-26 ng/ml 
for healthy Caucasian adults, and generally not beyond a minimum of 3 and a maximum 
80 ng/ml when the extreme values are considered (Karege et al., 2005; Trajkovska et al., 
2007; Yoshida et al., 2012). Therefore, a dilution step must be applied to process the 
samples, which may introduce a potential source of additional errors. Nevertheless, the 
results from our study suggest that all kits with the exception of Millipore-ChemikineTM, 
which appears to systematically underestimate BDNF concentration, are able to perform 
well in the range of concentrations of serum BDNF found in a healthy Caucasian 
population.  
The sandwich ELISA assays tested here differed also for the type of capture and detection 
antibodies. In addition, capture antibody are generally pre-coated, with the exception of the 
Promega kit, which requires preparation by the experimenter. The Millipore-Milliplex® kit 
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exploits the Luminex®/xMAP® technology, where magnetic microspheres, filled with a dye 
mixture, are coated with the capture antibody; this technology allows multiplexing and high 
throughput screening, but requires special equipment. Remarkably, the Biosensis kit is 
built on a unique strategy, because it uses the same antibody for both capture and 
detection, based on the fact that BDNF is naturally occurring as a dimer and therefore, 
once a monomer is captured, the other monomer is available for detection. The Biosensis 
kit provides also the quickest procedure (results in less than four hours for a full 96 well 
plate) while the kit by Promega, which is probably the most used, is time consuming (23-
25 hours), because it requires an overnight plate coating, another potential source of 
variability. 
Of note, the Promega kit resulted to be the only assay among those tested, for which the 
species-specificity was not declared, while the other kits were declared to be specific for 
detection of human BDNF. In addition, Biosensis and Millipore-ChemikineTM also can 
cross-react with BDNF from rodent species. Concerning the specificity for the different 
proteolytic forms of BDNF, four kits recognized both pro and mature BDNF forms while 
Aviscera-Bioscience and R&D System kits showed a remarkable preferential specificity for 
the mature form of BDNF, as indicated by the manufacturers. The ability of a diagnostic 
assay to distinguish between BDNF precursor and BDNF mature forms might represent a 
critical issue in specific clinical applications. Indeed, we recently proposed that altered 
biosynthesis of the different BDNF proteolytic forms may represent a common hallmark of 
neurological diseases with cognitive dysfunctions (Carlino et al., 2013; Carlino et al., 
2011). This hypothesis is based on studies in animal models and post-mortem human 
brains, which highlighted that different forms of learning and memory require either the 
pro-BDNF precursor or the mature BDNF form. In particular, decreased synthesis of 
mature BDNF, especially in hippocampus and prefrontal cortex, is associated with memory 
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loss and learning impairment; while decreased production of pro-BDNF in amygdala is 
associated with dysfunctions in emotional control and finally, alterations of both mature 
BDNF and pro-BDNF can affect several cognitive functions at the same time (Baj et al., 
2013a; Carlino et al., 2013). Of note, specific kits for detection of pro and mature BDNF 
forms are now becoming available (Riffault et al., 2014; Yoshida et al., 2012). It remains to 
be determined if the ELISA kits specific for pro-BDNF have sufficient sensitivity to be 
appropriate for clinical applications. 
Besides the technical issues discussed here, several studies investigated socio-
demographic determinants and other factors that may affect serum levels of BDNF such 
as gender, age, Body Mass Index (BMI), urbanicity, smoking status, and alcohol intake.  
While there are conflicting studies regarding BMI (Bus et al., 2011; Elfving et al., 2012; 
Lommatzsch et al., 2005; Monteleone et al., 2004; Ziegenhorn et al., 2007), concerning 
the effect of gender, our findings are in agreement with studies showing no gender 
difference regarding BDNF serum level (Bus et al., 2011; Lang et al., 2004; Lommatzsch 
et al., 2005; Ziegenhorn et al., 2007). However, it was also reported that BDNF in whole 
blood or plasma was higher in women compared to men (Elfving et al., 2010; Trajkovska 
et al., 2007) and several studies have suggested an interaction, with respect to circulating 
BDNF, between gender and age (Bus et al., 2011; Bus et al., 2012; Lommatzsch et al., 
2005; Suwa et al., 2006; Ziegenhorn et al., 2007). Serum BDNF resulted to be increased 
in association with Nicotine assumption (Jamal et al., 2014; Suriyaprom et al., 2013) and 
to be decreased in association with high alcohol intake (>2U/day), but not with moderate 
alcohol consumption (Bus et al., 2011; Elfving et al., 2012). A final note regards the 
putative effects of the Val66Met polymorphism in BDNF gene on the levels of serum 
BDNF. The large majority of studies reported no association between Val66Met and serum 
BDNF in Asiatic, European and American populations (Grande et al., 2014; Jamal et al., 
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2014; Katsuki et al., 2012; Suriyaprom et al., 2013; Yoshimura et al., 2011) as also 
summarized in a recent meta-analysis (Terracciano et al., 2013). It is worth mentioning 
however, that multiple regression analysis highlighted that the Val66Met polymorphism 
may affect serum levels of BDNF through a complex interaction with gender and in 
response to specific treatments such as IFN-α (Elfving et al., 2012; Lotrich et al., 2013) or 
linked to neurophysiologic response associated with working memory processes (Cerasa 
et al., 2010). These confounding factors are all to be taken in consideration in future 
studies aimed at defining a cut-off in serum BDNF concentration useful for diagnostic 
purposes. 
In conclusion, the availability of reliable blood-based biomarkers for diagnosis and therapy 
monitoring still remains a major unmet medical need in neurology and 
neuropsychiatry(Kapur et al., 2012; van Beveren and Hoogendijk, 2011). There is a 
general consensus that BDNF may represent an important measurable biomarker 
however, the poor reproducibility of BDNF measures has to date prevented its validation 
for clinical purposes. This study, by providing a methodology which reduces the high 
variability due to technical, pre-analytical and analytical steps provides the basis to obtain 
an accurate measure BDNF in human serum, suitable for future clinical applications. 
 
 5.2 AIM 2 
In the second part of the present work, also taking advantage of the methodology issues 
addressed for BDNF measurement, we undertook a research aimed at indentify 
associations between the scores of job-related stress indicators (in a healthcare assistants 
population) and the levels of circulating BDNF and other 48 biological markers, consisting 
in trophic factors and immune mediators such as cytokines and chemokines.  
92 
 
Work-related chronic stress is a condition that occurs when a person has, or feels, a high 
job demand having, however, low job control, thus felling unable to cope with the requests. 
Another means driving this kind of chronic stress is the alteration in the effort-reward 
balance (Siegrist et al., 2004), where a worker challenges demanding job but obtain 
improper remuneration, in term of salary, accomplishment or job perspectives. Job-related 
chronic stress is an emerging factor in the development of physical and mental illness 
(such as depression) and its effects can be explained well by the allostatic load model, 
similarly to what happen for other type of chronic stress. Job stress has high social costs, 
both in term of wellness (increased illness and injuries) and productivity (lower efficiency, 
high rate of absenteeism, etc.), thus European policies, since more than a decade, have 
recognized the work-related stress as an emerging occupational health risk which 
deserves identification, prevention and management like other work-related risks. The 
proposed methodology for stress risk assessment emphasizes the necessity to integrate 
subjective evaluations with objective measurements, to better identify subjects at risk to 
develop chronic work stress. 
Therefore, in our study, we attempt to couple the scores outcome from self-assessed 
questionnaires for the stress-risk evaluation (subjective assessments), with changes in 
circulating level of humoral mediators (objective measures), focusing in particular on 
trophic factors and immune mediators. The perceived stress at work was estimated by two 
means, using an instrument standardized for the Italian context, the Qu-BO test (Falco et 
al., 2012): three items by an Italian adaptation of the Maslach Burnout Inventory (Maslach 
et al., 2001), which evaluate burnout condition, a psychosomatic syndrome characterized 
by the three core dimensions of emotional exhaustion, feelings of depersonalization, and 
state of personal accomplishment; five items that evaluate job-related pshychophysical 
stress in term of increased anxiety, emotional status, gastrointestinal and cardiac 
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disturbances, along with ergonomic problems at the workplace (headache, hurting neck or 
shoulders or back pain). Our results highlighted a significant gender difference in the 
perceived job-stress. This is not surprisingly, since male and female are known to 
differently respond to stress, both acute and chronic (McEwen, 2007). In particular, we 
found that women had higher scores for all the items of psychophysical stress and for the 
dimension of emotional exhaustion in burnout. No sex difference for personal 
accomplishment was found, while men had higher scores of depersonalization. The 
putative effect of gender on burnout state remain to be verified, since previous study found 
either no difference (Moragon et al., 2005), or address burnout state only in female (Grossi 
et al., 2003) or male (Langelaan et al., 2007), while the majority of the study did not 
address this topic and applied gender control. Differently, the finding that women are more 
susceptible to job-related psychosocial stress is in line with evidences showing a higher 
tendency for female to develop stress-related pathology such as anxiety and depression 
(Altemus et al., 2014; Young and Altemus, 2004). This condition is potentially due to an 
estrogen-driven delayed shut off of the HPA axis (Goel et al., 2014; Kajantie and Phillips, 
2006). Brief considerations are of worth also for BMI and age. We found no association 
with burnout dimensions and BMI, in agreement with previous finding by Armon and 
colleagues (Armon et al., 2008). On the other hand, we observed a negative correlation 
with the psychophysical items, significant for anxiety, gastric problems and overall stress; 
however, we considered BMI as a covariate of gender, since it was significantly lower in 
female than in male and the interaction effect of gender-BMI did not associate with any of 
the scores in partial least square regression. All subsequent analysis for association with 
biochemical variables were therefore conducted controlling for both gender and BMI. 
Despite the well known positive association linking age and higher risk for allostatic load 
(Fischer et al., 2009), we did not found any correlation between age and both burnout and 
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psychophysical stress scores. Actually, this is not surprisingly, since the population of 
healthcare assistant under study comprised middle aged adults, within a comparable age 
range.  
Since chronic stress is known to influence immune functions, we decided to examine its 
effect on serum level of immune mediators, namely cytokines and chemokines. As a 
result, we found that higher score of psychophysical stress, but not burnout, were 
associated with lower serum concentration of some member from the chemokine family, in 
particular MCP-1/CCL2, RANTES/CCL5, CTACK/CCL27 and Eotaxin/CCL11. Since these 
chemokines are involved in immune cells migration and communications, our findings 
support the hypothesis that chronic stress induces suppression of both cellular and 
humoral response (Segerstrom and Miller, 2004). Interestingly, a previous study on 
German industrial workers showed that higher scores of effort-reward imbalance (Siegrist 
et al., 2004) predict lower bone-marrow derived progenitor cells (Fischer et al., 2009). 
Differently, other authors suggested an increased pro-inflammatory state in job-related 
chronic stress (Asberg et al., 2009; Bellingrath et al., 2010). As an example, healthy school 
teachers with high effort–reward-imbalance and overcommitment show increased 
production of IL-6 and TNF-α cytokines, which are mainly classified as pro-inflammatory 
(Bellingrath et al., 2010); they found, however, dampened innate immune defence in term 
of reduction in natural-killer (NK) cells, which are important players of the humoral 
immunity. It is important to note that in the mentioned study, subjects were exposed to 
acute laboratory stressor, consisting in Trier Social Stress test, before performing immune 
assessments. Similarly, other studies assessing the effects of chronic stress on immune 
system, before doing immune mediators titration, often performed brief mental tasks on 
subjects or challenged immune cells with lypopolisaccharid (LPS) in vitro (Gibb et al., 
2008; Lee et al., 2010) and these are potential confounders that make difficult to 
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disentangle the effect of acute stress, since is known to induce immune activation 
(Dhabhar, 2009).  
Monocyte Chemoattractant Protein-1 (MCP-1 or chemokine C-C motif Ligand 2, CCL2) is 
one of the best characterized chemokine, able to attract monocytes and basophils but not 
neutrophils or eosinophils. Has been categorized mainly as pro-inflammatory and 
implicated in different stress-related pathologies characterized by monocytic infiltrates, like 
psoriasis, rheumathoid arthritis or atherosclerosis (Amasyali et al., 2009). However, it 
augments monocyte anti-tumor activity and exploit also anti-inflammatory effects 
(Deshmane et al., 2009). Our observation of reduced circulating MIP-1/CCL2 protein in 
job-related stress dimensions (anxiety and gastric problems) are apparently in contrast 
with previous finding on psychosocial stress in women made by Asberg and colleagues 
(2009), as they found increased level of MCP-1 and also trophic factors, namely VEGF 
and EGF, in stressed workers. However, they included in the study a heterogeneous group 
of long-term sickleave subjects diagnosed for any affective or stress-related mental 
disorder (depression, anxiety disorder, stress disorder, burnout syndrome, exhaustion 
disorder); in addition, they performed parametric analysis on non-transformed, non-
normally distributed data, thus increasing type I error probability, specifically the possibility 
to reject a true null hypothesis.  
Of note, MCP-1/CCL2, as well as other chemokines, can be produced centrally by 
microglia and astrocytes, and also neurons, and plays important roles in both physiological 
and pathological brain conditions. For example, high MCP-1 reactivity has been found in 
neurons and plaques of Alzheimer patients (Sokolova et al., 2009), in white-matter 
hippocampal lesions of multiple sclerosis subjects (Prins et al., 2014; Yao and Tsirka, 
2014)and has been shown to compromise the blood-brain-barrier integrity (Yao and 
Tsirka, 2014). However, maintaining doses of MCP-1have neuroprotective effects, 
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independently of microglia/macrophages infiltration, on retinal ganglion cells in an 
experimental model of glaucoma (Chiu et al., 2010). A role of MCP-1 has been suggested 
also in mental disorders: a negative correlation between peripheral MCP-1 and cognition 
was found in persons experiencing first psychotic episodes (Martinez-Cengotitabengoa et 
al., 2012) and higher levels of MCP-1 have been described in major depressive subjects 
(Young et al., 2014). On the other hand, lower chemokine levels, including MCP-1/CCL2 
and Eotaxin/CCL11, were found in cerebrospinal fluid (CSF) of suicide attempters respect 
to healthy controls (Janelidze et al., 2013). 
We observed also negative associations between CTACK/CCL27 and the scores of 
anxiety, gastric and cardiac problems as well as overall stress dimension. Cutanous T-cell 
attracting chemokine (CTACK or C-C motif ligand 27, CCL27) is a chemotactic factor 
mediating the homing of lymphocytes to cutaneous sites. Interestingly, high anxious mice 
showed lowered CTACK, associated with an increased skin cancer burden in all stage of 
tumour development, with respect non-anxious animals (Dhabhar et al., 2012). We found 
also negative associations between the scores of anxiety and ergonomic problems at the 
workplace and the chemokines RANTES/CCL5 and Eotaxin/CCL11. Both chemokines are 
considered mainly pro-inflammatory and are involved in the recruitment and function of 
eosinophils. However, at the moment, the literature concerning in particular job-related 
stress is not sufficient to support or disprove our findings. Besides, Eotaxin was found 
reduced in CSF of suicide attempters (Janelidze et al., 2013) and RANTES increased in 
schizophrenic patients but not in major-depressive subjects (Domenici et al., 2010). 
Intriguingly, we found increased interleukin 17 (IL-17) in subject reporting gastric problems. 
IL-17 is a feature cytokine of the T-helper 17, which are important players in the Th1/Th2 
balance regulation and have a role in autoimmunity disease. IL-17 is associated with 
tissue damage in brain, joints, heart, lungs and intestines in experimental models 
97 
 
(Steinman, 2007). Alterations in Th17 function have been suggested also for depressive 
disorders (Beurel et al., 2013; Schmidt et al., 2010; Zhou et al., 2013). Interestingly, in a 
model of chronic psychosocial stress, stressed mice developed spontaneous colitis and 
gut inflammation and the effects were mediated by Th17 activity and IL-17 increased 
production (Schmidt et al., 2010). Furthermore, in our study, we observed a positive 
association between serum BDNF and the score of ergonomic problems at the workplace. 
A previous study on Japanese subjects with job-related stress pointed out a reduction 
trend in circulating BDNF (Mitoma et al., 2008). Differently, another study found that 
chronically perceived stress increases serum BDNF levels (Feder et al., 2009). Of note, 
BDNF levels are highly dynamic in response to stress and also vary across different brain 
regions (Gray et al., 2013); for example, increase BDNF levels have been found in 
amygdala while reduction has been described in prefrontal cortex and hippocampus, 
during chronic stress. Our observation of a BDNF increment in chronic stress could be the 
result of induction of compensatory protective mechanism. Despite the possible 
connection between BDNF circulating levels and brain levels, however, we cannot draw 
any conclusion regarding neither the central effect of the peripheral BDNF changes, nor 
the causality of the alterations in stress conditions. These considerations can be applied 
also to the observation concerning chemokines and cytokines levels: both acute and 
chronic stress are known to induce even rapid redistribution of leukocytes from blood and 
lymphoid streams to compartments and vice versa (Dhabhar, 2009), thus we cannot 
exclude that the observed reduction in circulating chemokine levels occurring in job-related 
chronic stress are due to compartmentalization of immune cells blood to lymph nodes or 
other sites such as skin or intestine. In addition, our results should be seen as preliminary 
given other intrinsic limitations of this study: 1) the study design involved only one single 
time point, thus the results may suffer for short time course variations. 2) Scores of work-
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related stress resulted to be positive skewned, meaning our study population have mild to 
low chronic stress; therefore results need to be replicated in a more stressed population. 
3) The sample size was relatively small compared to the number of biological marker 
considered, thus increasing the possibility of over-fitting problems. 4) We did not control for 
other primary mediators such as metabolic indicators (blood pressure, cholesterol) or 
urinary excretion of cortisol, adrenaline and noradrenaline, thus limiting the possibility to 
identify an allostatic load index. 5) Lastly, we did not check for historical and socio-
economical statuses which are confounders that potentially influence the response to 
stress; however, our population was relatively homogenous in that sense, since was 
extract from the same environment. In addition, immune alterations are hard to predict 
given the enhancing versus suppressive effects of stress on immune function (Dhabhar, 
2009). 
Despite these limitations, we believe our study adds some valuable insight in immune 
mediator changes occurring in conditions of work-related chronic stress. The few biological 
variable identified deserve further investigations as they can be potential objective 
indicators to be coupled with the subjective assessments of job-related stress. However, 
replications with larger samples, possibly on a longitudinal study analyzing the effect of 
intervention aim to reduce stressing situations at work, are warranted. As a future 
perspective, to identify potential relations between the chemokine reduction and brain 
effects, in particular on hippocampal pyramidal neurons, we will inhibit chemokine 
receptors on stressed organotypic hippocampal slice, or primary cultures, extracted from 
wild type mice, and evaluate the effects on dendrites and spines morphology. 
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 5.3 AIM 3 
In the last part of the project, we aimed at investigating how chronic cytotoxic stress impact 
on the BDNF production at a cellular level, in a stress model consisting of SK-N-BE 
neuroblastoma cells treated with cisplatin in condition of serum free medium. Of note, this 
cell line has been previously used as an in vitro stress model to test the effect of 
corticosteron administration (Sun et al., 2010) or to study oxidative processes in Alzheimer 
and Parkinson’s diseases (Batelli et al., 2008; Gamba et al., 2011). Considering the role of 
BDNF in neuroblastoma tumours, previos studies suggested that BDNF and its receptor 
TrkB are involved in an autocrine loop that promote cell survival and resistance to 
chemotherapy (Baj and Tongiorgi, 2009; Jaboin et al., 2002). Here, we demonstrate that 
cisplatin treatment and serum deprivation, in particular after 24 hour, are able to increase 
both total BDNF and single mRNA transcripts of all 5’ UTR exons, with the exceptions of 
exons 5 and 8. These findings overlap with previous observation from our lab by which 
silencing of exons 4 and 6 result in a significant reduction of SK-N-BE viability under 
cytotoxic stress conditions (Baj and Tongiorgi, 2009). In addition, we found that 
transcription enhancement is coupled with a delayed but significant increased in BDNF 
protein production. Furthermore, cisplatin stress insult also boost translation of a firefly 
reporter gene embedded within both 5’ and 3’ UTRs of BDNF, highlighting the involvement 
of mechanisms that control BDNF translation induction, in particular in condition of 
cytotoxic stress. In particular, we observed that cisplatin improve translation of all tested 
transcript, consisting in exons 1, 2c, 4 or 6 along with 3’UTR long sequence. As already 
known, BDNF comes as a unique protein encoded by a single coding sequence (CDS), so 
all the complexity in its regulation is due to the presence of multiple untranslated regions, 
which are alternatively spliced to give rise, in humans, to 34 mRNA transcripts, each of 
them is independently transcribed (Aid et al., 2007; Pruunsild et al., 2007; Pruunsild et al., 
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2011). Has been already demonstrated that different BDNF mRNA variants target different 
cell compartments, especially in neurons, in an activity dependent manner (Tongiorgi et 
al., 1997); for example, exons 1, 3, 5, 7, 8 and 9a preferentially segregate to soma, exon 4 
to proximal while exons 2 and 6 to distal dendrites (Baj et al., 2013b; Baj et al., 2011). 
Hence, they display also different ability to translate in response to various compounds 
(Vaghi et al., 2014).  
How cytotoxic stress induced by cisplatin can promote BDNF translation? Cisplatin [cis-
diamminedichloro platinum(II)] is a metal compound commonly used in clinic as antitumor 
drug that induces cell damage mainly by cross-linking genomic DNA and, to a lesser 
extent, proteins. As known, DNA damage triggers different phenomena: on one side, 
causes cell death by necrosis (mainly by PARP-induced ATP depletion) (Fuertes et al., 
2003) and/or apoptosis (both via intrinsic and extrinsic programmed cell death pathways, 
leading to final activation of caspase-3-6-7) (Zhou et al., 2002). On the other hand, DNA 
damage promotes cell cycle arrest, DNA repairing mechanisms and activation of cell 
survival pathways. These pathways require functional activity of transduction mediators, 
some of which are shared in the BDNF signaling cascade, like Akt, ERK and mTOR, and 
are known to control both gene expression and protein translation (Cepeda et al., 2007; 
Cunha et al., 2010). The translation ability of an mRNA resides in its UTR regions and the 
presence of a 5’ cap, secondary structures, multiple upstream AUGs (uAUGs) and open 
reading frames (ORFs), internal ribosome entry sites (IRESs) and the binding of trans-
acting factors are all relevant for translation regulation. These features can control the 
synthesis of a protein by affecting stability of the mRNA, its accessibility to ribosomes, 
circularization and interaction with the translation machinery (Vaghi et al., 2014). Despite 
that, the mechanisms regulating translation of BDNF variants are still unknown. However, 
a potential mechanism that has been described for CPE-containing α-Ca2+/calmodulin-
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dependent protein kinase II (αCaMKII) mRNA, in both Xenopus oocytes and at 
hippocampal neuron synapses, involve the cytoplasmic polyadenilation-induced translation 
of dormant mRNAs (Huang et al., 2002). According to this mechanism, the CPE element 
(UUUUUAU) in the 3’UTR is bound by the CPE binding protein (CPEB) and Maskin that, in 
quiescent conditions, is associated to the m7G cap-binding subunit, the elongation factor 
4E (elF4E). This dormant state prevent the association between elF4E and elF4G, the 
initiation starter, and mRNAs are characterized by short poly(A) tails. Upon stimulation, the 
cascade events cause the phosphorylation of CPEB that recruit the multisubunit cleavage 
and polyadenilation specificity factor (CPSF) to a downstream element of CPE, the 
AAUAAA sequence; this event probably attract active poly(A) polymerase (PAP) to the 
mRNA end. The subsequent polyadenilation causes Maskin to dissociate from elF4E 
which is then free to bind elF4G, thereby recruiting the 40S ribosomal subunit to mRNA 
and start scanning the sequence for the initiation codon (Pestova et al., 1998). The critical 
event is the phosphorylation of CPEB on Ser174, which is mediated by Aurora kinase. 
Aurora proteins are a family of serine/threonine kinases primarily implicated in several 
mitosis events and cell cycle control (Fu et al., 2007). Of note, tumours with increased 
Aurora activity are associated with a more malignant phenotype (Maris, 2009). 
Considering that BDNF transcripts bear the CPE element in 3’UTR, we hypothesised for 
BDNF a translation induction mechanism mediated by Aurora kinase, similar to those 
described above for αCaMKII mRNAs. Therefore, blocking Aurora activity by using the 
PHA-680632 inhibitor (Soncini et al., 2006), we would expect a dual effect: increased cell 
mortality, due to altered cell cycle control and a decreased BDNF protein production as a 
result of a reduced translation induction. In contrast, while we observed an increased cell 
death, although only in combination with cisplatin treatment, we also found unexpectedly, 
an increase in BDNF protein production, mainly driven by transcripts bearing the exon 6. 
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Noteworthy, exon 6 transcripts have been reported to be both transcriptionally and 
translationally repressed in resting conditions, pointing out a tight regulation of translation 
(Baj and Tongiorgi, 2009; Vaghi et al., 2014). Here we show that exon6 transcripts also 
play a crucial role in providing a BDNF source under stressing conditions.  
Our results are not conclusive, since we did not check for other mechanisms, therefore 
other study are warranted. Despite we cannot exclude an involvement of Aurora kinase, 
other mechanisms for translation induction are likely to occur and we can speculate on 
some of them based on the current literature. For example, BDNF pathway downstream to 
TrkB receptors was shown to facilitate local translation at synapses by activation of mTOR 
via PI3K; both mTOR and ERK are able to regulate the assembly of the elF4E complex, 
contributing to translation induction (Schratt et al., 2004), so it is conceivable if BDNF 
contribute to its own production by such mechanism. In addition, other non-canonical ways 
for translation induction are possible, especially during stressful conditions. Hence, for 
example, ribosomal shunting provides a way to bypass mRNA secondary structure 
complexes, which usually causes the ribosome to dissociate in the classical scanning 
model (Hellen and Sarnow, 2001; Yueh and Schneider, 1996). Other mRNAs, like those 
for elongation factors and ribosomal proteins, contain a 5’ terminal oligo pyrimidine 
sequence (5’ TOP) that acts as a translational regulatory element. Another important 
means for translation initiation is represent by the internal ribosome entry site (IRES), 
which are complex secondary structure in 5’ non-translated regions that, with the aid of 
other trans-acting factors, direct the recruitment of ribosomal subunits in a 5’-cap 
independent manner. IRES-driven mechanism was at first described for picornaviral 
mRNAs direct translation (Jang et al., 1988) but, after that, many eukaryotic mRNAs have 
shown to display IRES properties; these include many transcription factors, oncogenes, 
elongation factors, apoptotic activators and growth factors like FGF2, PDGF-b and VEGF 
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(Hellen and Sarnow, 2001). It is worth of note that several of these IRES-containing 
mRNAs encode proteins that are produced as a response to a variety of stress situations, 
such as inflammation, angiogenesis and cytotoxic drugs (Hellen and Sarnow, 2001; 
Johannes et al., 1999). Unfortunately, to our knowledge, IRES structure in BDNF mRNAs 
have not been described so far and deserve further investigations. Another level of 
complexity is added by the fact that translation and mRNA degradation are in competition 
with each other but linked by a dynamic process, referred to as the mRNA Cycle, in which 
mRNP granules known as P-bodies and stress granules plays a pivotal role in control 
translation (Decker and Parker, 2012). 
In conclusion, our results pointed toward a BDNF translation induction mechanism that is 
Aurora kinese independent, at least in conditions of cytotoxic stress. Furthermore, the 
observations made could have important clinical implications in the use of Aurora inhibitors 
as adjuvant in neuroblastoma treatment as, even if increase cell mortality, they facilitate 
the selection of resistant cells that further enhance BDNF production. 
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6. CONCLUDING REMARKS 
 
In the present Thesis, we addressed an important topic regarding the inconsistency of 
assessments of peripheral BDNF protein from body fluids and provide a standardized 
methodology, at both pre analytical and analytical stages,that we believe would aid to 
reduce the variability of serum BDNF measurements among studies, making it suitable for 
potential clinical applications. Secondly, we provide support to the hypothesis that work-
related chronic stress causes an imbalance in immune response, with a generalized 
suppression, as we found reduced circulating chemokine to be associated with high scores 
of many stress indicators; interestingly, we also observed a positive association with 
serum BDNF with one of the stress item, suggesting a possible involvement in 
mechanisms concerning chronic stress protection. Lastly, we gave evidences that BDNF is 
implicated protection from stressful insults at cellular level, at least in a neuroblastoma cell 
line treated with the chemotherapeutic drug cisplatin plus an Aurora kinase inhibitor as 
adjuvant. Further studies will address, in vitro, the neuronal effects of the inhibition of 
chemokines in presence or absence of BDNF trophic support, both in primary and 
hippocampal slice cultures. 
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